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  Abstract	  	  
Mycobacterium	   tuberculosis	   protein-­‐tyrosine-­‐phosphatase	   B	   (MptpB)	   is	   a	  secreted	   virulence	   factor	   that	   subverts	   antimicrobial	   activity	   in	   the	   host.	   We	  report	  here	  the	  structure-­‐based	  design	  of	  selective	  MptpB	  inhibitors	  that	  reduce	  survival	  of	  multidrug-­‐resistant	  tuberculosis	  strains	  in	  macrophages	  and	  enhance	  killing	  efficacy	  by	  first-­‐line	  antibiotics.	  Monotherapy	  with	  an	  orally	  bioavailable	  MptpB	   inhibitor	   reduces	   infection	   burden	   in	   acute	   and	   chronic	   guinea-­‐pig	  models	   and	   improves	   the	   overall	   pathology.	   Our	   findings	   provide	   a	   new	  paradigm	  for	  tuberculosis	  treatment.	  
	  
	   	  
	  Introduction	  
Tuberculosis	   (TB)	   remains	   a	  major	  health	  problem	  and	   leading	   cause	  of	   death	  worldwide.	  Antibiotic	  resistance	  is	  a	  main	  obstacle	  in	  the	  cure	  and	  eradication	  of	  TB,	   with	   over	   half	   a	   million	   new	   cases	   of	   drug-­‐resistant	   TB	   per	   year.	   More	  alarming	  is	  the	  increasing	  number	  of	  extensive	  or	  untreatable	  drug-­‐resistant	  TB	  cases	   (WHO	   TB	   Report	   2017).	   Critical	   to	   the	   pathogenesis	   of	  Mycobacterium	  
tuberculosis,	   the	  causative	  agent	  of	  TB,	   is	   the	  secretion	  of	  virulence	  factors	   that	  subvert	   the	   innate	   immune	   response	   and	   prevent	   bacterial	   control	   by	   host	  macrophages	   1,	   2.	   In	   this	   context,	   anti-­‐virulence	   drugs	   targeting	   the	   pathogen	  survival	   mechanisms	   may	   represent	   an	   efficient	   complementary	   strategy	   to	  antibiotics	  to	  increase	  efficacy	  and	  assist	  in	  clearing	  the	  infection.	  Anti-­‐virulence	  strategies	  are	  now	  emerging	  as	  promising	  therapies	  to	  counterbalance	  antibiotic	  resistance	  in	  a	  number	  of	  microbial	  infections	  including	  TB3,	  4,	  5,	  6,7,	  and	  yet	  this	  is	  a	  largely	  unexploited	  area	  in	  the	  clinic.	  	  
One	   such	   virulence	   factor	   is	   the	   MptpB	   phosphatase	   that	   is	   secreted	   into	   the	  cytoplasm	   of	   host	   macrophages8.	   MptpB	   is	   critical	   for	   M.	   tuberculosis	   intra-­‐macrophage	   survival	   and	   for	  persistence	  of	   the	   infection	   in	   animal	  models9,	   10,	  and	  acts	  by	  both	  attenuating	  the	  bactericidal	  immune	  responses	  and	  promoting	  host	   cell	   survival.	   We	   report	   here	   that	   selective	   inhibition	   of	   MptpB	   impairs	  survival	  of	  multi-­‐drug	   resistant	   (MDR)	  TB	   in	  human	  macrophages	  and	  reduces	  infection	   burden	   in	   acute	   and	   chronic	   guinea-­‐pig	   models.	   Furthermore,	  inhibition	   of	  MptpB	   enhances	  mycobacterial	   killing	   by	   the	   first-­‐line	   antibiotics	  rifampicin	  (RIF)	  and	   isoniazid	  (INH).	   	  Previously	  we	  have	  reported	   that	  MptpB	  dephosphorylates	   in	   vitro	   the	   key	   signalling	   lipids	   phosphatidylinositol	   3-­‐
	  phosphate	  (PI3P)	  and	  phosphatidylinositol	  3,5-­‐biphosphate	  (PI(3,5)P2)11.	  These	  lipids	   control	   critical	   steps	   of	   phagolysosomal	   biogenesis	   and	   bacterial	  clearance12.	  	  We	  hypothesised	  that	  inhibition	  of	  MptpB	  activity	  may	  thus	  restore	  the	  intrinsic	  host	  response	  compromised	  by	  this	  virulence	  factor,	  offering	  a	  novel	  therapeutic	   mechanism	   against	  M.	   tuberculosis	   infections.	   Since	   MptpB	   is	   not	  essential	   for	   extracellular	   growth10,	   its	   inhibition	   could	   prove	   a	   distinct	  therapeutic	   advantage	   over	   antibiotics	   as	   it	   would	   potentially	   inflict	   less	  selective	  pressure	  and	  reduce	  acquired	  drug	  resistance.	  An	  additional	  advantage	  is	  that	  to	  block	  the	  secreted	  MptpB	  there	  is	  no	  need	  for	  drug	  delivery	  across	  the	  complex	   and	   poorly	   permeable	   mycobacterial	   cell-­‐wall.	   The	   lack	   of	   a	   human	  orthologue	  also	  makes	  MptpB	  an	  attractive	  drug	  target	  for	  specific	  and	  selective	  therapy.	  	  
Crucially,	   we,	   and	   others,	   have	   demonstrated	   that	   MptpB	   inhibitors	   impair	  mycobacterial	   survival	   in	   macrophages13,14,15,	   supporting	   our	   hypothesis.	   	   Our	  initial	   isoxazole-­‐based	   MptpB	   inhibitors	   displayed	   modest	   potency	   and	  selectivity13.	   Other	   reported	   potent	   MptpB	   inhibitors	   showed	   little	   efficacy	   in	  animal	   models15	   indicating	   that	   optimisation	   of	   both	   target	   affinity	   and	  pharmacokinetics	  are	  needed	  to	  develop	  compounds	  with	  in	  vivo	  efficacy.	  	  
We	   report	   here	   the	   rational	   structure-­‐based	   development	   of	   our	   initial	   C1	  isoxazole	  inhibitor	  13	  to	  generate	  a	  new	  series	  of	  MptpB	  inhibitors	  with	  improved	  potency,	  selectivity	  and	  cell	  activity.	  Furthermore,	  an	  analogue	   from	  this	  series	  showed	   an	   excellent	   pharmacokinetics	   profile,	   oral	   bioavailability	   and	   in	   vivo	  efficacy	  in	  guinea	  pig	  models	  of	  tuberculosis	  infection.	  
	  	  
Results	  and	  Discussion	  
The	   structure	   of	   MptpB16	   has	   an	   unusually	   large	   active	   site,	   with	   a	   primary	  phosphate-­‐binding	  pocket	  (P1)	  and	  two	  unique	  secondary	  pockets	  (P2	  and	  P3)	  not	  present	   in	  human	  phosphatases.	   In	  the	  crystallographic	  structure	  of	  MptpB	  with	   an	   oxalylamino-­‐methylene-­‐thiophene	   sulphonamide	   inhibitor17,	   the	  oxalylamino	  group	  binds	  to	  P1	  whereas	  the	  sulphonamide	  partially	  occupies	  P2.	  Molecular	   docking	   of	   our	   C1	   inhibitor13	   indicated	   that	   the	   isoxazole	   group	  binded	   to	   P1	   and	   P3,	   but	   P2	   remained	   unoccupied	   (Fig.	   1).	   Our	   strategy	   to	  develop	  this	  initial	  hit	  used	  a	  structure-­‐based	  rational	  approach	  aimed	  to	  retain	  binding	   at	   P1	   and	   P3	   (isoxazole	   warhead)	   whilst	   exploiting	   binding	   at	   P2	   to	  increase	  potency	  and	  selectivity,	  see,	  for	  example,	  structures	  2	  and	  5	  (Scheme	  1,	  Figure	  1).	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Figure	  1.	  Rational	  structure-­‐based	  design	  of	  MptpB	  inhibitors.	  a)	  Active	  site	  of	  MptpB	  with	   compounds	  C1	   (cyan)	   13	   and	  5	   (orange)	   docked.	   The	   isoxazole	  head	   in	  C1	   and	  5	   occupy	   the	   P1	   pocket	   (P-­‐loop)	   and	   neighbouring	   P3	   pocket,	  whereas	   the	   additional	   dichloro-­‐phenol	   group	   in	   5	   occupies	   P2.	   b)	   The	   poor	  activity	   of	   the	   isoxazole	   head	   alone	   and	   that	   of	   the	   intermediates	   of	   the	   series	  confirms	  that	  binding	  at	  P2	  is	  essential	  to	  achieve	  higher	  potency.	  	  Computational	  screening	  of	  commercial	  fragment	  libraries	  using	  a	  genetic	  based	  algorithm18,	  19	  and	  the	  structure	  of	  MptpB17	  identified	  >300	  motifs	  interacting	  at	  P2,	   providing	   suitable	   starting	   points	   for	   the	   design	   of	   a	   new	   series	   of	   4,5-­‐diarylisoxazole-­‐3-­‐carboxylic	  acids	  (Scheme	  2).	  







































Scheme	  2	  Isoxazoles	  identified	  for	  synthesis.	  
	  
Synthesis	  of	  4,5-­‐diarylisoxazole-­‐3-­‐carboxylic	  acids	  	  
Isoxazoles	  1	  –	  13	  were	  identified	  for	  synthesis	  (Scheme	  2).	  The	  synthesis	  of	  4,5-­‐diarylisoxazole-­‐3-­‐carboxylic	   acids	   1	   –	   4	   is	   outlined	   in	   Scheme	   3.	   Methyl	   5-­‐phenylisoxazole-­‐3-­‐carboxylate	  14	   is	  well	  known	  20,	  21	  and	  was	  synthesized	  from	  acetophenone	   by	   a	   slight	   modification	   of	   literature	   procedures	   (see	  experimental).	   Following	   bromination	   of	   the	   methyl	   carboxylate	   14,	   Suzuki	  couplings	   of	   the	   bromoisoxazole	  15	   22	  with	   phenyl-­‐,	   3-­‐methoxyphenyl-­‐	   and	   3-­‐hydroxyphenyl-­‐boronic	  acids	  gave	   the	  4,5-­‐diarylisoxazole-­‐3-­‐carboxylates	  16	   23,	  
17	   and	  18.	   Saponification	   of	   these,	   and	   the	   isoxazolecarboxylate	  14,	   gave	   the	  corresponding	  carboxylic	  acids	  1	  –	  4.	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  diarylisoxazole-­‐3-­‐carboxylate	  22.	   This	  was	   hydrolysed	   to	   give	   the	   isoxazole-­‐3-­‐carboxylic	  acid	  5	  ready	  for	  screening,	  see	  Scheme	  4.	  	  
	  
Scheme	  3.	  Synthesis	  of	  the	  4,5-­‐diarylisoxazole-­‐3-­‐carboxylic	  acids	  1	  -­‐	  4	  Reagents	  and	  conditions:	  i,	  NaOH,	  MeOH,	  THF,	  rt,	  1	  h	  (1,	  65%;	  2,	  60%;	  3,	  50%;	  4,	  55%);	  ii,	  NBS,	   TFA,	   heat	   under	   reflux	   48	   h	   (64%);	   iii,	   ArB(OH)2,	   Na2CO3,	   DMF,	  bis(triphenylphosphine)palladium(II)	  dichloride	  or	  Pd(Ph3P)4,	  90	  oC,	  1	  –	  3	  h	  (16,	  80%;	  17,	  42%;	  18,	  49%).	  
	  
Scheme	   4.	   Preparation	   of	   the	   isoxazole-­‐3-­‐carboxylic	   acid	   5	   Reagents	   and	  conditions:	   i,	   (CF3SO2)2O,	   py.,	   DCM,	   0	   oC	   to	   rt,	   90	   min	   (94%);	   ii,	  bis(pinacolato)diboron,	   [1,1ʹ′-­‐bis(diphenylphosphino)ferrocene]palladium(II)	  dichloride,	  dioxane,	  90	  oC,	  18	  h	  (59%);	  iii,	  19,	  21,	  DMF,	  Na2CO3,	  Pd(PPh3)4,	  90	  oC,	  3	  h	  (45%);	  iv,	  NaOH,	  MeOH,	  rt,	  1	  h	  (81%).	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  experimental).	  Analogous	  chemistry	  was	  used	  to	  prepare	  the	  5-­‐methylisoxazole-­‐3-­‐carboxylic	  acid	  13	  from	  the	  known	  methyl	  4-­‐bromo-­‐5-­‐methylisoxazole	  24,	  see	  Scheme	  5.	  
	  
Scheme	  5.	  Preparation	  of	  the	  5-­‐methylisoxazole-­‐3-­‐carboxylic	  acid	  13	  Reagents	  and	   conditions:	   i,	   NBS,	   TFA,	   0	   oC,	   heat	   under	   reflux,	   16	   h;	   ii,	   ArB(OH)2,	   aq.	  NaHCO3,	  DMF,	  Pd(Ph3P)2Cl2,	  90	  oC,	  5	  h	  (28%);	  iii,	  (CF3SO2)2O,	  py.,	  DCM,	  0	  oC	  to	  rt,	  6	  h	  (66%);	  iv,	  21,	  Pd(Ph3P)4	  ,	  DMF,	  90	  oC,	  3	  h;	  v,	  NaOH,	  MeOH,	  0	  oC,	  1	  h	  (65%).	  	  	  
	  
Activity	   of	   the	   4,5-­‐diarylisoxazole-­‐3-­‐carboxylic	   acids	   and	   biochemical	  
validation	  
The	   initial	   isoxazole	   fragment	   alone	   1	   showed	   very	   poor	   inhibition,	   but	   the	  introduction	  of	  a	  phenyl	  ring	  at	  the	  4-­‐position	  reduced	  the	  IC50	  from	  >500	  µM	  	  1	  to	   17	   µM	   2.	   Extending	   the	   aromatic	   ring	   with	   a	   di-­‐chlorophenol	   fragment,	  identified	  in	  the	  computational	  screen,	  afforded	  a	  further	  reduction	  to	  0.9	  µM	  5.	  Improved	   binding	   for	   the	   new	   compounds	   was	   accompanied	   with	   increased	  selectivity	  over	  the	  human	  phosphatase	  hPTP1B	  from	  1.6-­‐fold	  for	  compound	  C1	  to	  5.9-­‐fold	   for	   compound	  2	   and	  141-­‐fold	   for	   compound	  5	   (Fig.	  1b),	   supporting	  the	  notion	  that	  binding	  at	  P2	  is	  critical	  for	  selectivity.	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  correlation	  between	  the	  estimated	  free	  energy	  of	  binding	  and	  the	  experimental	  activity	   (Supplementary	  Table	   1).	  Molecular	   docking	   confirmed	   that	   additional	  binding	   at	   P2	   was	   responsible	   for	   the	   significant	   increase	   in	   potency	   of	   5	  compared	  to	  compounds	  2	   -­‐	   4.	  Subsequently,	  we	  explored	  variations	  of	   the	  di-­‐chlorophenol	  fragment	  substituents	  in	  the	  derivatives	  6	  -­‐	  12	  (Table	  1).	  	  
The	  double	  and	  triple	  substituted	  aromatic	  groups	  showed	  similar	  IC50	  to	  5.	  The	  introduction	   of	   the	   NO2	   group	   at	   the	   meta-­‐position	   of	   the	   phenyl	   ring	   12	  increased	  potency	  by	  50	  %	  with	  respect	  to	  5	  resulting	  in	  an	  IC50	  of	  0.4	  μM,	  and	  afforded	  an	  excellent	  selectivity	  over	  human	  phosphatases	  (900-­‐fold	  for	  PTP1B)	  and	  the	  M.	  tuberculosis	  phosphatase	  MptpA	  (Table	  1).	  	  
Our	  models	  suggested	  that	  the	  para-­‐OH	  group	  of	  the	  phenyl	  ring	  (P2	  head),	  could	  form	   hydrogen	   bonds	   with	   the	   Oε1	   of	   E129	   (Fig.	   2a)	   and	   that	   the	  meta-­‐NO2	  group	  in	  12	  could	  form	  additional	  interactions	  with	  R136	  or	  H94	  thus	  explaining	  its	   increased	   potency.	   Mutational	   analysis	   of	   the	   P2	   pocket	   residues	   validated	  this	  mode	  of	  binding.	  Mutations	  of	  E129	  to	  alanine	  showed	  a	  2	  to	  5-­‐fold	  decrease	  in	   inhibition	  (Fig.	  2b),	  while	  mutation	  of	  H94	  or	  R136	  had	  a	  milder	  effect	   (~2-­‐fold	  decrease).	  	  
	  
	  
	   	  
	  Table	   1.	   Inhibitory	   activity	   of	   the	   4,5-­‐diarylisoxazole-­‐3-­‐carboxylic	   acids	  














 IC50 (µM) 
P2 Head Compound MptpB MptpA hPTP1B hVHR 
 
5 0.92 ± 0.03 33.7 ± 0.6  127 ± 9 10.5 ± 0.5 
 
6 2.8 ± 0.3 74 ± 1.0 >100 54.0 ± 4.6 
 
7 2.3 ± 0.7 95 ± 5.0 >100 59 ± 1.0 
 
8 1.2 ± 0.3 6.5 ± 0.3 48 ± 3  12.3 ± 1.0 
 
9 1.1 ± 0.1 36 ± 2.0 >100 23.2 ± 0.3 
 
10 0.9 ± 0.1 23.5 ± 0.5 213 ± 29  18.7 ± 1.5  
 
11 1.5 ± 0.1 35.3 ± 3.1 >100 40.2 ± 1.3  
 























Figure	  2.	  Binding	  at	  the	  P2	  pocket	  is	  important	  for	  the	  efficacy	  of	  the	  new	  
series	  of	  MptpB	  inhibitors.	  a)	  Mode	  of	  binding	  of	  the	  representative	  compound	  










! Compound WT H94A E129A R136A 
5 0.92 ± 0.03 1.3 ± 0.3 2.4 ± 0.1 1.0 ± 0.2 
7 2.3 ± 0.7 2.4 ± 0.2 7.0 ± 1.2 2.3 ± 0.5 
8 1.2 ± 0.3 2.9 ± 0.8 5.9 ± 0.8 2.6 ± 0.3 
9 1.1 ± 0.1 2.2 ± 0.3 5.7 ± 0.9 2.1 ± 0.1 
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  established	   using	   one-­‐way	   ANOVA,	   Dunnett’s	   test	   (****p-­‐value	   <	   0.0001,	  **p=0.012).	  Inset	  shows	  viability	  of	  treated	  macrophages.	  
	  
The	   new	   MptpB	   inhibitors	   reduce	   mycobacterial	   burden	   in	   macrophage	  
infections	  	  
Next	   we	   tested	   the	   efficacy	   of	   the	   new	   compounds	   in	   reducing	   mycobacterial	  survival	   in	  macrophage	   infections.	  The	  new	  series	  of	  compounds	  showed	  dose-­‐dependent	   efficacy	   in	   reducing	   intracellular	   mycobacterial	   (BCG)	   burden	   in	  mouse	  macrophages	  (J774)	  up	  to	  87%	  after	  72h	  of	  infection	  compared	  to	  control	  (DMSO	   treated)	   (Fig.	   2c).	   These	   findings	   are	   consistent	   with	   MtpB	   inhibition	  assisting	  bacterial	  clearance	   in	  host	  macrophages,	  even	   in	   the	  absence	  of	   INF-­‐γ	  activation	  (see	  methods).	  The	  new	  compounds	  show	  increased	  efficacy	  at	  80	  µM	  (except	   for	  5)	   compared	   to	   our	   initial	   C1	   isoxazole	   inhibitor,	   thus	   correlating	  with	  the	  higher	  potency	  of	  the	  new	  series.	  Toxicity	  of	  the	  new	  compounds	  is	  low	  as	   shown	   in	   the	   cell	   survival	   assays	   (Fig	   2c	   inset),	   with	   only	   compound	   10	  showing	   a	   substantial	   effect	   (>23%	   reduction)	   on	   cell	   viability	   at	   >	   100	   µM	  doses.	  
The	  new	  series	  of	  compounds	  displayed	  moderate	  permeability	  and	  lipophilicity	  (logD),	   good	   solubility,	   they	  were	   stable	   in	  plasma	  with	  moderate	   clearance	   in	  human	  liver	  microsomes,	  and	  high	  plasma	  protein	  binding	  (Suppl.	  Table	  2).	  They	  also	   showed	   poor	   in	   vivo	   pharmacological	   properties	   in	   guinea-­‐pigs,	   with	   a	  bioavailability	   below	   13%	   (Table	   2).	   	   We	   then	   replaced	   the	   phenyl	   ring	   at	  position	  5	  of	  the	  isoxazole	  by	  a	  methyl	  group	  to	  reduce	  the	  bulk	  and	  number	  of	  rings	  in	  the	  compound,	  generating	  	  compound	  13.	  The	  potency	  of	  compound	  13,	  
	  at	  3	  µM,	  was	  lower	  than	  the	  best	  of	  the	  parent	  series	  of	  inhibitors	  5	  and	  12	  (by	  3-­‐7	   fold),	   possibly	   due	   to	   reduced	   hydrophobic	   interactions	   at	   the	   P3	   pocket.	  However,	   compound	  13	   showed	   very	   good	   kinetic	   solubility	   (200	  µM),	   and	   a	  good	   PAMPA	   value	   (78.1	   nM/s)	   suggesting	   a	   potential	   good	   cell	   penetration,	  despite	   showing	   a	   higher	   lipophilicity	   than	   the	   parent	   series	   (logD	   4)	   (see	  Supplementary	   material	   for	   details).	   Importantly,	   compound	   13	   displayed	  improved	   pharmacological	   properties,	   it	   is	   orally	   bioavailable	   and	   has	   an	  excellent	  phamacokinetic	  profile	  (Table	  2),	  therefore	  it	  was	  selected	  for	  further	  evaluation	  of	  its	  cell	  activity	  and	  efficacy	  in	  animal	  models	  of	  infection.	  	  
	  
Table	  2.	  Pharmacokinetic	  parameters	  for	  MptpB	  inhibitors.	  Compounds	  3,	  8,	  9	   and	   13	   were	   tested	   in	   guinea-­‐pigs	   to	   determine	   their	   PK	   profile.	   Cmax	   was	  observed	  at	  0.5	  hr	  after	  IP	  (intraperitoneal)	  dosing	  and	  at	  0.25	  hr	  after	  PO	  (oral)	  dosing.	  	  
	  *High	   bioavailability	   may	   be	   due	   to	   prolonged	   absorption	   after	   the	   oral	   dose	  
limiting	  the	  rate	  of	  elimination;	  BLQ,	  below	  limit	  of	  quantification.	  	  
Compound 13 (lead) 5 8 9 
 Guinea pig Guinea pig Guinea pig Guinea pig 
Route IP Oral IP Oral IP Oral IP Oral 
Dose (mg/kg) 4 8 2.5 5 1.25 3.5 2.5 5 
Cmax (ng/mL) 31519 111099 3714 BLQ 746 BLQ 197 BLQ 
t1/2 (hr) 1.4 5.1 0.7 BLQ 1.3 BLQ 1.4 BLQ 
AUCinf (ng.hr/mL) 71854 230407 4968 BLQ 1742 BLQ 399 BLQ 
Bioavailability   156%*   <4%   <13%   <2.5% !
	  MptpB	   inhibitors	   reduce	   survival	   of	   multidrug-­‐resistant	   strains	   in	  
macrophages	  and	  enhance	  killing	  by	  first-­‐line	  antibiotics	  
Investigation	   of	   compound	   13	   desmonstrated	   that	   it	   also	   exhibits	   dose-­‐dependent	   efficacy	   in	   reducing	   intracellular	   mycobacterial	   (BCG)	   burden	   in	  mouse	   macrophages	   (J774)	   up	   to	   84%	   (Fig.	   3b),	   yet	   it	   does	   not	   affect	  extracellular	   bacterial	   growth	   (Fig	   3c),	   thus	   confirming	   that	   inhibition	  exclusively	   targets	   intracellular	  mycobacteria,	  as	  expected.	  Critically,	   treatment	  with	   compound	   13	   also	   reduces	   the	   intracellular	   mycobacterial	   burden	   in	  human	   macrophages	   (THP1),	   up	   to	   63%	   when	   using	   a	   drug-­‐susceptible	   M.	  
tuberculosis	  strain	  (H37Rv),	  or	  up	  to	  74%	  when	  using	  a	  MDR	  strain	  (Beijing-­‐”W”)	  (Fig.	   3d).	   	   A	   similar	   effect	   was	   observed	   for	   the	   initial	   C1	   compound	  (Supplementary	   Figure	   1)	   demonstrating	   that	   efficacy	   in	   reducing	   MDR-­‐TB	  survival	  is	  a	  general	  quality	  of	  MptpB	  inhibitors.	  	  
To	   test	  whether	  compound	  13	   is	   compatible	  with	   first-­‐line	  TB	  drugs,	   isoniazid	  (INH)	  and	  rifampicin	  (RIF),	  we	  determined	  doses	  of	  these	  antibiotics	  that	  caused	  <	  25%	  reduction	  in	  the	  bacterial	  burden	  of	  macrophages	  (0.1µg/ml	  for	  INH	  and	  0.3	   µg/ml	   for	   RIF,	   Fig.	   3e).	   We	   then	   used	   these	   doses	   of	   INH	   and	   RIF	   in	  combination	  with	  a	  low	  dose,	  5	  µM,	  of	  compound	  13.	  The	  combination	  resulted	  in	  >	  93%	  reduction	  in	  bacterial	  burden	  (Fig.	  3e).	  Thus,	  treatment	  in	  combination	  with	  compound	  13	  enhances	  killing	  by	  current	  anti-­‐tubercular	  drugs.	  This	  is	  an	  important	   finding	   since	   tuberculosis	   treatments	   rely	   on	   drug	   combination	  therapies	  to	  clear	  the	  infection.	  
	  	  
Figure	   3.	   Compound	   13	   reduces	   intracellular	   bacterial	   burden	   of	   H37Rv	  
and	   MDR-­‐TB	   in	   macrophage	   infections.	   	   a)	   Structure	   of	   compound	   13.	   b)	  Effect	  of	  dose-­‐dependent	  treatment	  with	  compound	  13	  on	  mycobacterial	  burden	  (BCG)	  in	  infected	  mouse	  macrophages	  (J774)	  at	  72	  hours	  post	  infection	  (****p	  <	  0.0001,	  ***p	  <	  0.0004,	  *p	  <	  0.04	  by	  one-­‐way	  ANOVA,	  Dunnett’s	  test).	  	  Inset	  shows	  macrophage	   viability	   upon	   treatment	   with	   13	   (**p=0.01).	   c)	   Extracellular	  growth	  of	  BCG	  is	  not	  affected	  by	  treatment	  with	  compound	  13	  (80	  µM)	  respect	  to	   DMSO	   control.	   d)	   Treatment	   with	   compound	   13	   (20	   or	   100	   µM)	   reduces	  intracellular	  survival	  of	  an	  MDR	  strain	  (Beijing-­‐W)	  and	  of	  the	  drug-­‐susceptible	  M.	  
tuberculosis	  H37Rv	  strain	   in	  human	  THP1	  macrophages	  (grey).	  Controls	  on	  the	  effect	   on	   extracellular	   bacterial	   growth	   are	   shown	   (black),	   **p=0.0021;	   ***	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  MptpB	   inhibition	   alters	   phagosomal	   phosphoinositde-­‐3-­‐phosphate	  
dynamics	  during	  infection	  
MtptB	  dephosphorylates	  PI3P	  and	  PI(3,5)P2	  in	  vitro11,	  two	  important	  anchors	  of	  Rab	   proteins	   that	   drive	   phagosomal	   maturation	   and	   clearance	   of	   infection.	  However,	   we	   do	   not	   know	   its	   effect	   on	   cellular	   PI	   dynamics.	   	   We	   tested	   if	  compound	  13	   affected	  PI3P	  dynamics	  on	  M.	  tuberculosis-­‐phagosomes.	  For	   that,	  we	  monitored	  PI3P	  localisation	  by	  live-­‐cell	  imaging	  in	  macrophages	  expressing	  a	  fluorescent	   PI3P-­‐binding	   module	   (FYVE2X-­‐EGFP)	   after	   infection	   with	  fluorescently	   labelled	   M.	   tuberculosis	   H37Rv24.	   	   PI3P	   associated	   with	   M.	  
tuberculosis-­‐phagosomes	  immediately	  after	   infection,	  but	  PI3P	  signal	  decreased	  rapidly	   after	  2-­‐4	  minutes	   as	  previously	   reported24.	  However,	   in	   the	  13-­‐treated	  macrophages,	  the	  peak	  of	  PI3P	  was	  prolonged	  up	  to	  12	  minutes	  (Fig.	  4).	  The	  data	  indicate	  that	  MptpB	  inhibition	  extends	  the	  presence	  of	  PI3P	  and	   its	  association	  with	   M.	   tuberculosis-­‐phagosomes,	   suggesting	   a	   role	   for	   MptpB	   in	   host	  phosphoinositide	  metabolism	  as	  hypothesised	  from	  its	  in	  vitro	  activity11.	  
	   	  
	  	  
	  
Figure	   4.	   MptpB	   inhibition	   alters	   phagosomal	   PI3P	   dynamics.	   Spatio-­‐temporal	   dynamics	   of	   PI3P	   (as	   visualised	   by	   expression	   of	   EGFP-­‐FYVE)	   on	  M.	  
tuberculosis	  containing	  phagosomes	  (top	  figure).	  The	  plot	  shows	  the	  quantitative	  analysis	  of	  the	  association	  of	  EGFP-­‐FYVE	  to	  PI3P	  at	  the	  phagosomal	  membrane,	  during	   the	   first	   20	   minutes	   of	   phagocytosis	   (data	   from	   3	   independent	  experiments).	   Treatment	   with	   13	   extends	   the	   peak	   of	   PI3P	   up	   to	   12	   min.	  compared	  to	  the	  rapid	  decay	  of	  PI3P	  peak	  in	  the	  untreated	  phagosomes	  (DMSO	  control).	   	   DMSO,	   control	   for	   untreated	   macrophages	   (RAW264.7);	   cpd	   13,	  macrophages	  treated	  with	  compound	  13.	  	  	  	  
Monotherapy	  with	  an	  orally	  bioavailable	  MptpB	  inhibitor	  reduces	  infection	  
burden	  in	  acute	  and	  chronic	  guinea-­‐pig	  models	  
In	  vivo	   profiling	  of	   compound	  13	   showed	  high	  exposure	   (Cmax	  112	  µg/ml,	  AUC	  230	  µg.hr/ml),	   long	   half-­‐life	   (t1/2	   5	   hours),	   good	   oral	   availability	   and	   relevant	  tissue	   distribution	   in	   guinea-­‐pigs,	   upon	   parental	   and	   oral	   dosing	   (Table	   2	   and	  Supplementary	  Fig.	  3),	  making	  it	  suitable	  for	  efficacy	  studies	  in	  animal	  models	  of	  infection.	  Tolerability	  studies	  with	  13	  at	  50,	  or	  100	  mg/kg	  	  (dosing	  once	  daily	  for	  7	   days)	   showed	   no	   adverse	   drug	   effects	   and	   weight	   increases	   of	   >5%	   was	  






















	  observed	  in	  all	  animals	  during	  the	  tolerability	  trial.	  	  Compound	  13	  was	   then	  assessed	   for	  efficacy	  as	  monotherapy	   in	   the	  acute	   and	  
chronic	  guinea-­‐pig	  models	  of	  TB	  infection.	  	  For	  the	  acute	  infection,	  animals	  were	  infected	  with	  96	  CFU	  (avg.	  ±	  27	  SEM),	  and	  after	  24hrs,	  orally	  dosed	  once	  daily	  with	   compound	   13	   for	   4	   weeks.	   Treatment	   resulted	   in	   a	   0.9	   log	   reduction	   of	  bacterial	  burden	  in	  the	  lungs	  relative	  to	  vehicle.	  	  For	  the	  chronic	  infection,	  guinea	  pigs	   were	   infected	   with	   63	   CFU	   (avg.	   ±	   18	   SEM),	   and	   treatments	   were	   orally	  administered	  daily	  for	  4	  weeks	  starting	  at	  28	  days	  post	  infection.	  Treatment	  with	  compound	  13	  resulted	  in	  at	  least	  1	  log	  reduction	  in	  bacterial	  burden	  in	  lungs	  and	  spleens	  (Fig.	  5a	  and	  Supplementary	  Table	  3).	  	  
Pathological	  differences	  were	  observed	  between	  13	  and	  vehicle	   treated	  groups	  in	  both	   lungs	  and	  spleens	   (Fig	  5b-­‐e)	   from	  both	   the	  acute	  and	  chronic	   infection	  studies.	   Although	   the	   total	   number	   of	   tubercles	   were	   similar	   in	   both	   13	   and	  vehicle	  treated	  animals,	  larger	  tubercles	  were	  consistently	  present	  in	  all	  vehicle	  group.	  Overall,	   less	   damage	   to	   the	   spleens	   and	   lungs	  were	   observed	   in	   the	  13	  treated	  group	  relative	  to	  the	  vehicle	  only	  group.	  	  
Inspection	   of	   the	   lungs	   and	   spleens	   after	   56	   days	   of	   infection	   revealed	   visible	  necrotic	  lesions	  ranging	  from	  ~1	  to	  4	  mm,	  with	  more	  consolidation	  observed	  in	  the	   vehicle	   group	   than	   in	   the	   compound	   13	   treated	   group,	   and	   with	   organs	  presenting	  up	  to	  19%	  increase	  in	  weight	  respect	  to	  the	  13	  treated	  group	  (Suppl.	  Table	  4).	  The	  histopathological	  analysis	  of	  the	  vehicle	  treated	  lungs	  and	  spleens	  displayed	   large	   and	   diffuse	   confluent	   granulomas	   with	   necrotising	   cores	   and	  inflammation	  throughout	  the	  parenchyma,	  pathology	  typically	  associated	  with	  a	  chronic	   infection.	   	   The	   compound	   13	   treated	   lungs	   and	   spleens	   showed	   an	  
	  improvement	   in	   the	   pathology	   with	   fewer	   smaller	   lesions	   and	   reduced	  inflammation	  both	  in	  lungs	  and	  spleens	  (Fig.	  5e).	  	  
















Figure	  5.	  MptpB	  inhibition	  reduces	  bacterial	  burden	  in	  animal	  models	  and	  
improves	  pahtology.	  	  a)	  Efficacy	  of	  monotherapy	  treatment	  with	  13	  for	  28	  days	  in	   the	   acute	   and	   chronic	   guinea-­‐pig	   models	   of	   TB	   (female	   Hartley	   Duncan).	  Treatment	   was	   with	   13	   (100	   mg/kg))	   or	   RIF	   (50mg/kg)	   orally	   administered	  once	  daily;	  VEH,	  vehicle	  control.	  Bars	  represent	  the	  mean	  value	  (±SEM)	  of	  CFUs	  from	   4-­‐5	   animals.	   Statistical	   significance	   is	   indicated	   (*	   p	   <	   0.05	   by	   one-­‐way	  ANOVA,	  Dunnett’s	  test).	  b)	  and	  c)	  Gross	  pathological	  scoring	  of	  the	  TB	  infected	  guinea-­‐pig	  lungs	  (b)	  and	  spleens	  (c)	  based	  on	  Jain	  et	  al.	  27	  The	  lungs	  and	  spleen	  from	  individual	  animals	  were	  given	  a	  score	  from	  1	  to	  4	  based	  on	  the	  number	  and	  size	   of	   tubercles,	   level	   of	   involvement,	   inflammation	   and	   necrosis.	   	   Bars	  represent	   the	   mean	   value	   (±SEM)	   of	   CFUs	   from	   4-­‐5	   animals.	   Statistical	  significance	   is	   indicated	   (*	   p	   <	   0.05	   by	   one-­‐way	   ANOVA,	   Dunnett’s	   test).	   d)	  Representative	   images	   of	   tissues	   at	   56	   days	   post	   infection	   (chronic	   model)	  showing	  reduction	  of	  the	  number	  granuloma	  in	  the	  compound	  13	  treated	  lungs	  and	  spleen.	  e)	  Representative	  histopathological	   images	   from	   lungs	  and	  spleens	  at	   56	   days	   post	   infection	   from	   (chronic	   model).	   Lungs	   and	   Spleens	   fixed	   in	  neutral	  buffer	  formalin	  were	  sectioned	  (5	  micron)	  and	  stained	  with	  hematoxylin	  and	   eosin	   (H&E)	   and	   imaged	   at	   10x	   magnification.	   Vehicle	   treated	   lungs	   and	  spleen	  show	  an	  increased	  presence	  of	  granulomatous	  infiltration	  (black	  arrows)	  and	  pathologic	  damage	  relative	  to	  compound	  13	  treated	  lungs	  and	  spleen.	  Bars	  represent	  2	  mm.	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  Conclusions	  In	   summary,	   our	   structure-­‐guided	   drug	   development	   approach,	   exploiting	  unique	   features	   in	   the	   MptpB	   structure,	   has	   delivered	   an	   orally	   bioavailable	  compound	   with	   excellent	   therapeutic	   properties.	   We	   have	   demonstrated	   that	  MptpB	  inhibitors	  are	  selective,	  effective	  against	  MDR-­‐TB	  and	  that	  they	  increase	  the	   intracellular	   killing	   efficacy	   of	   first	   line	   antibiotics	   RIF	   and	   INH,	   indicating	  their	   suitability	   for	   combination	   therapies.	   	   Notably,	   reduction	   of	   intracellular	  survival	   occurs	   in	   the	   absence	   of	   macrophage	   pre-­‐activation	   with	   IFNγ,	  suggesting	   that	   this	   strategy	  may	  be	  particularly	   advantageous	  when	   impaired	  macrophage	   activation	   fails	   to	   control	   the	   infection	   (i.e.	   immuno-­‐compromised	  patients).	  	  
Importantly,	  our	  lead	  compound	  showed	  	  efficacy	  in	  reducing	  bacterial	  burden	  in	  a	  clinically-­‐relevant	  guinea-­‐pig	  model	  of	  infection,	  as	  well	  as	  improvement	  in	  the	  pathology	   of	   lungs	   and	   spleen.	   This	   is	   also	   consistent	   with	   the	   enhanced	  pathology	  and	  reduced	  inflamation	  observed	  when	  the	  mptpB	  gene	  is	  mutated9.	  This	  is	  the	  first	  proof	  of	  concept	  that	  MptpB	  inhibitors,	  used	  as	  monotherapy,	  can	  significantly	  reduce	  infection	  burden.	  A	  previous	  study15	  showed	  a	  mild	  effect	  (<	  0.5	   log	   reduction)	   when	   both	   MptpA	   and	   MptpB	   inhibitors	   where	   added	   to	   a	  cocktail	  of	  three	  first-­‐line	  antibiotics,	  isoniazid−	  rifampicin−pyrazinamide (HRZ),	  effectively	   a	   5-­‐drug	   combination.	   However,	   there	   was	   no	   effect	   on	   bacterial	  burden	  when	  only	  MptpA	  or	  MptpB	   inhibitors	  were	  added	  to	   the	  HRZ	  cocktail.	  No	   data	   were	   presented	   on	   monotherapy	   treatments	   with	   either	   MptpA	   or	  MptpB	  inhibitors,	  thus	  no	  direct	  comparison	  can	  be	  made	  with	  our	  results.	  	  	  
	  Renewed	   interest	   in	   developing	   anti-­‐virulence	   agents	   for	   TB	   treatment	  (reviewed	   in3,	   4,	   5,	   6,7)	   makes	   this	   study	   timely.	   Furthermore,	   MptpB	   inhibitors	  could	   be	   developed	   into	   broad-­‐spectrum	   anti-­‐virulence	   drugs,	   as	   MptpB	  orthologues	  are	  present	  in	  more	  than	  50	  human	  pathogens	  including	  C.	  difficile,	  
E.	  faecalis,	  K.	  pneumoniae,	  Yesinia	  spp	  and	  L.	  monocytogenes	  28,29.	  	  
Anti-­‐virulence	   drugs	   hold	   great	   promise	   for	   the	  management	   of	   TB	   infections.	  The	   current	   challenges	   in	   eradicating	  TB	   include:	   prevention	  with	   the	   existing	  BCG	  vaccine	  has	   limited	  efficacy;	  standard	  treatments	  with	  antibiotics	  are	   long,	  complex	   and	   chronic	   drug	   exposure	   over	   a	   prolonged	   period	   is	   linked	   to	  development	   of	   drug	   resistance;	   and	   host-­‐directed	   therapies	   are	   difficult	   to	  control	   because	   they	   are	   patient-­‐dependent.	   Anti-­‐virulence	   agents	   offer	  advantages	  to	  overcome	  these	  challenges	  because	  their	  action	  is	  independent	  of	  the	  host	  fitness	  and	  they	  have	  the	  potential	  to	  limit	  drug	  resistance.	  Our	  findings	  suggest	   that	  MptpB	   inhibition	   offers	   a	   new	   paradigm	   for	   TB	   therapy	  with	   the	  potential	  to	  treat	  MDR-­‐TB,	  improve	  antibiotic	  efficacy	  and	  overall	  pathology.	  
	  	  
	   	  
	  Experimental	  Methods	  	  
Synthetic	  Chemistry	  
General	  experimental	  details	  All	   reactions	   were	   carried	   out	   under	   an	   atmosphere	   of	   dry	   nitrogen	   unless	  otherwise	   stated.	   Low-­‐resolution	  mass	   spectra	  were	   recorded	   on	   a	  Micromass	  Trio	  200	   spectrometer	  using	   electron	   impact	   (EI)	   ionisation	  or	   electrospray	   in	  positive	   (ES+)	   or	   negative	   modes	   (ES-­‐).	   High-­‐resolution	   mass	   spectra	   were	  recorded	  on	  a	  Kratos	  Concept	   IS	  spectrometer.	   Infrared	  spectra	  were	  recorded	  on	  a	  Genesis	  FTIR	  as	  evaporated	   films	  on	   sodium	  chloride	  plates.	  Proton	  NMR	  spectra	  (1H	  NMR)	  and	  carbon	  NMR	  spectra	  (13C	  NMR)	  were	  recorded	  on	  Bruker	  (500	  MHz),	  Varian	  Unity	  500	  (500	  MHz),	  Varian	  INOVA	  400	  (400	  MHz)	  or	  Varian	  INOVA	   Unity	   300	   (300	   MHz)	   spectrometers.	   Residual	   non-­‐deuterated	   solvent	  was	  used	  as	  internal	  standard.	  Chemical	  shifts	  (δH	  and	  δC)	  are	  quoted	  in	  parts	  per	  million	  (ppm)	  downfield	  from	  tetramethylsilane	  (TMS).	   	  Flash	  column	  chromatography	  was	  carried	  out	  using	  silica	  gel	  60H	  from	  Merck.	  Light	  petroleum	  refers	  to	  the	  fraction	  that	  boils	  between	  40	  oC	  and	  60	  oC	  and	  was	  distilled	  prior	  to	  use.	  Ether	  refers	  to	  diethyl	  ether	  that	  was	  used	  without	  further	  purification.	  Tetrahydrofuran	  was	  dried	  over	  sodium/benzophenone	  and	  was	  distilled	  under	  a	  nitrogen	  atmosphere.	  DCM	  was	  dried	  over	  calcium	  hydride	  and	  distilled	  under	  an	  atmosphere	  of	  nitrogen.	  All	   other	   reagents	  and	   solvents	  were	   used	   as	   purchased	   unless	   otherwise	   stated.	   The	   purity	   of	   compounds	  submitted	   for	  screening	  was	  determined	   to	  be	  greater	   than	  95%	  by	  HPLC	  (see	  supplementary	  data	  for	  copies	  of	  the	  HPLC	  traces)	  	  
	  5-­‐Phenylisoxazole-­‐3-­‐carboxylic	  acid	  (1);	  standard	  procedure	  30	  31	  Aqueous	   sodium	   hydroxide	   (2	   M,	   2.7	   mL,	   5.4	   mmol)	   was	   added	   to	   methyl	   5-­‐phenylisoxazole-­‐3-­‐carboxylate	  14	   (219	  mg,	  1.08	  mmol)	   in	  MeOH:THF	  (1:1	  v/v,	  60	  mL)	  at	  rt	  and	  the	  mixture	  was	  stirred	  for	  1	  hour.	  Water	  was	  added	  (60	  mL)	  and	   the	  mixture	  acidified	   to	  pH	  1	  using	  aqueous	  hydrogen	  chloride	   (2	  M)	   then	  concentrated	   under	   reduced	   pressure	   to	   give	   a	   slurry	   that	  was	   extracted	  with	  EtOAc	   (3	  ×	  60	  mL).	  The	  organic	  extracts	  were	  dried	   (NaSO4)	  and	  concentrated	  under	  reduced	  pressure	   to	  give	  an	  off-­‐white	  solid	   that	  was	  recrystallised	   (light	  petroleum:EtOAc,	  100:1	  v/v)	  to	  give	  the	  title	  compound	  1	  as	  a	  white	  solid	  (132	  mg,	   0.7	   mmol,	   65%);	   mp:	   162.8	   –	   163.8	   oC	   (lit.	   31	   160-­‐161	   oC);	   TLC	   (light	  petroleum:EtOAc,	  50:50	  v/v,	  with	  0.1%	  TFA):	  Rf	  =	  0.3;	  HPLC	   (silica,	  EtOAc	  with	  0.1	  %	  TFA):	   retention	   time	  3.27	  min,	  100	  %;	   1H	  NMR	  (500	  MHz,	  DMSO-­‐d6):	  δ	  14.13	  (br.	  s,	  1H),	  7.96	  (d,	  J	  8.0	  Hz,	  2H),	  7.59-­‐7.54	  (m,	  3	  H),	  7.44	  (s,	  1H);	  13C	  NMR	  (125	  MHz,	  DMSO-­‐d6):	  δ	  170.8,	  160.9,	  157.8,	  130.9,	  129.3,	  126.2,	  125.8,	  100.9;	  IR	  (film):	  3126,	  3055,	  2611,	  2512,	  1703,1474,	  1445,	  1261,	  995,	  914,	  820,	  760,	  686	  cm-­‐1.	  	  	  
4,5-­‐Diphenylisoxazole-­‐3-­‐carboxylic	  acid	  (2)	  23	  Following	  the	  procedure	  outlined	  for	  the	  preparation	  of	  carboxylic	  acid	  1,	  methyl	  4,5-­‐diphenylisoxazole-­‐3-­‐carboxylate	  16	   (90	  mg,	  0.32	  mmol)	   in	  MeOH:THF	   (1:1	  v/v,	   6	   mL)	   and	   aqueous	   sodium	   hydroxide	   (2	   M,	   0.8	   mL,	   1.6	   mmol),	   after	  recrystallisation	  (light	  petroleum:EtOAc,	  100:1	  v/v)	  gave	  the	  title	  compound	  2	  as	  a	   white	   solid	   (51	   mg,	   0.2	   mmol,	   60%);	   mp:	   134.5-­‐135.3	   oC;	   TLC	   (light	  petroleum:EtOAc,	  50:50	  v/v	  with	  0.1%	  TFA):	  Rf	  =	  0.36;	  HPLC	  (silica,	  EtOAc	  with	  
	  0.1	  %	  TFA):	   retention	   time	  3.18	  min,	  100	  %;	   1H	  NMR	  (500	  MHz,	  DMSO-­‐d6):	  δ	  13.65	  (br.	  s,	  1H),	  7.51	  -­‐	  7.32	  (m,	  10H);	  13C	  NMR	  (125	  MHz,	  DMSO-­‐d6):	  δ	  177.9,	  161.0	  151.8,	  130.0,	  129.1,	  128.6,	  128.4,	  126.6,	  116.2;	  IR	  (film):	  3058,	  1711,	  1429,	  1225,	  968,	  770,	  693	  cm-­‐1;	  LRMS	  (m/z,	  ES-­‐):	  220	  ([M	  -­‐	  45]-­‐,	  100%);	  HRMS	  (m/z):	  [M	  +	  H]+,	  calcd.	  for	  C16H12NO3,	  266.0812;	  found,	  266.0817.	  	  
4-­‐(3-­‐Methoxyphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylic	  acid	  (3)	  Following	  the	  procedure	  outlined	  for	  the	  preparation	  of	  carboxylic	  acid	  1,	  4-­‐(3-­‐methoxyphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	   17	   (100	   mg,	   0.32	   mmol)	   in	  MeOH:THF	   (1:1	   v/v,	   6	   mL)	   and	   aqueous	   sodium	   hydroxide	   (2	   M,	   0.8	   mL,	   1.6	  mmol),	  after	  recrystallisation	  (MeOH:H2O,	  50:1	  v/v)	  gave	  the	  title	  compound	  3	  as	  a	   white	   solid	   (47	   mg,	   0.16	   mmol,	   50%);	   mp:	   162.5-­‐163.5	   oC;	   TLC	   (light	  petroleum:EtOAc,	  50:50	  v/v	  with	  0.1%	  TFA):	  Rf	  =	  0.25;	  HPLC	  (silica,	  EtOAc	  with	  0.1	  %	  TFA):	   retention	   time	  3.20	  min,	  100	  %;	  1H	  NMR	  (500	  MHz,	  DMSO-­‐d6):	  δ	  13.94	  (br.	  s,	  1H),	  7.49-­‐7.42	  (m,	  5H),	  7.35	  (t,	  J	  8.0	  Hz,	  1H),	  7.01	  (dd,	  J	  2.0,	  8.0	  Hz,	  1H),	  6.95	  (m,	  1H),	  6.91	  (d,	  J	  7.5	  Hz,	  1H),	  3.73	  (s,	  3H);	  13C	  NMR	  (125	  MHz,	  DMSO-­‐
d6):	  δ	  166.0,	  160.9,	  159.2,	  156.3,	  130.6,	  130.2,	  129.7,	  129.0,	  126.7,	  126.4,	  122.2,	  115.9,	  115.7,	  113.8,	  55.1;	   IR	   (film):	  3154,	  1727,	  1621,	  1580,	  1439,	  1276,	  1227,	  1189,	  1095,	  1042,	  1008,	  966,	  878,	  826,	  805,	  768,	  689	  cm-­‐1;	  LRMS	  (m/z,	  ES-­‐):	  250	  ([M	  -­‐	  45]-­‐,	  100%);	  HRMS	  (m/z,	  ES-­‐):	   [M	  -­‐	  CO2H]-­‐	  calcd.	   for	  C16H12NO2,	  250.0873;	  found,	  250.0861.	  	  
	  
	  
	  4-­‐(3-­‐Hydroxyphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylic	  acid	  (4)	  Following	  the	  procedure	  outlined	  for	  the	  preparation	  of	  carboxylic	  acid	  1,	  methyl	  4-­‐(3-­‐hydroxyphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	  18	   (150	  mg,	   0.52	  mmol)	  in	  MeOH:THF	  (1:1	  v/v,	  10	  mL)	  and	  aqueous	  sodium	  hydroxide	  (2	  M,	  1.5	  mL,	  3	  mmol),	  after	  recrystallisation	  (MeOH:H2O,	  50:1	  v/v)	  gave	  the	  title	  compound	  4	  as	  a	  white	  solid	  (80	  mg,	  0.29	  mmol,	  55%);	  TLC	  (light	  petroleum:EtOAc,	  50:50	  v/v	  with	  0.1%	  TFA):	  Rf	   =	  0.5;	  HPLC	   (silica,	   EtOAc	  with	  0.1	  %	  TFA):	   retention	   time	  3.22	  min,	  100	  %;	  1H	  NMR	  (500	  MHz,	  DMSO-­‐d6):	  δ	  14.04	  (br.	  s,	  1H),	  9.56	  (s,	  1H),	  7.49-­‐7.41	  (m,	  5H),	  7.22	  (t,	  J	  8.0	  Hz,	  1H),	  6.81	  (d,	  J	  7.5	  Hz,	  1H),	  6.75-­‐6.72	  (m,	  2H);	  IR	   (film):	   3468,	   3243,	   3064,	   1722,	   1629,	   1583,	   1474,	   1444,	   1331,	   1228,	   1176,	  971,	   867,	   795,	   766,	   687	   cm-­‐1;	   LRMS	   (m/z,	   ES+):	   282	   ([M	  +	   1]+,	   100%);	   HRMS	  (m/z,	  ES+):	  [M	  +	  H]+	  calcd.	  for	  C16H12NO4,	  282.0761;	  found,	  282.0753.	  	  
4-­‐(3ʹ′ ,5ʹ′-­‐Dichloro-­‐4ʹ′-­‐hydroxy-­‐3-­‐biphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylic	  
acid	  (5)	  Following	  the	  procedure	  outlined	  for	  the	  preparation	  of	  carboxylic	  acid	  1,	  methyl	  4-­‐(3ʹ′,5ʹ′-­‐dichloro-­‐4ʹ′-­‐hydroxy-­‐3-­‐biphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	   22	  (900	   mg,	   2.04	   mmol)	   in	   MeOH:THF	   (25	   mL,	   4:1	   v/v)	   and	   aqueous	   sodium	  hydroxide	   (2	   M,	   5.11	   mL,	   10.2	   mmol),	   after	   recrystallisation	   (light	  petroleum:EtOAc,	  10:1	  v/v)	  gave	  the	  title	  compound	  5	  as	  a	  white	  solid	  (700	  mg,	  1.65	  mmol,	   81%);	  mp:	   187.5-­‐188.0	   oC;	   TLC	   (light	   petroleum:EtOAc,	   50:50	   v/v	  with	  0.1%	  TFA):	  Rf	   =	  0.5;	  HPLC	   (silica,	   EtOAc	  with	  0.1	  %	  TFA):	   retention	   time	  2.79	  min,	  100	  %;	  1H	  NMR	  (500	  MHz,	  DMSO-­‐d6):	  δ	  14.02	  (br.	  s,	  1H),	  10.35	  (s,	  1H)	  and	   7.75-­‐7.32	   (m,	   11H);	   13C	   NMR	   (125	  MHz,	   DMSO-­‐d6):	   δ	   166.3,	   160.9,	   156.2,	  148.6,	  137.5,	  132.4,	  130.6,	  129.6,	  129.2,	  129.0,	  128.1,	  126.8,	  126.6,	  126.5,	  126.3,	  
	  122.8,	  116.0;	  IR	  (film):	  3056,	  1717,	  1468,	  1430,	  1291,	  1161,	  1024,	  868,	  794,	  768,	  691	  cm-­‐1;	  LRMS	  (m/z,	  ES-­‐):	  426	  ([M	   -­‐	  1]-­‐,	  6%),	  424	  ([M	   -­‐	  1]-­‐,	  8),	  382	  ([M	  –	  45]-­‐,	  65),	   380	   ([M	  –	   45]-­‐,	   100);	   HRMS	   (m/z,	   ES-­‐):	   [M	   -­‐	   H]-­‐	   calcd.	   for	   C22H12NO435Cl2,	  424.0148;	  found,	  424.0154.	  	  
4-­‐(4ʹ′-­‐Hydroxy-­‐3-­‐biphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylic	  acid	  (6)	  Following	   the	   procedure	   outlined	   for	   the	   preparation	   of	   the	   methyl	   4-­‐biphenylisoxazole-­‐3-­‐carboxylate	  22,	  the	  aryl	  triflate	  19	  (300	  mg,	  0.7	  mmol)	  and	  4-­‐hydroxyphenylboronic	  acid	  (107	  mg,	  0.77	  mmol)	  in	  DMF	  (7	  mL)	  together	  with	  Pd(PPh3)4	   (8	   mg,	   0.007	   mmol),	   after	   repeated	   chromatography	   (Et2O:light	  petroleum,	   20:80	   -­‐	   40:60	   v/v,	   then	   with	   DCM)	   gave	   methyl	   4-­‐(4ʹ′-­‐hydroxy-­‐3-­‐biphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	   as	   a	   white	   solid	   (159	   mg,	   0.427	  mmol,	  61%);	  mp:	  62.7-­‐63.5	  oC;	  TLC	  (Et2O:light	  petroleum,	  40:60	  v/v):	  Rf	  =	  0.14;	  
1H	  NMR	  (500	  MHz,	  CDCl3):	  δ	  7.61-­‐7.57	  (m,	  3H),	  7.54	  (s,	  1H),	  7.48	  (t,	  J	  7.5	  Hz,	  1H),	  7.43	  (d,	  J	  9.0	  Hz,	  2H),	  7.39	  (d,	  J	  7.5	  Hz,	  1H),	  7.36-­‐7.33	  (m,	  2H),	  7.29	  (d,	  J	  7.5	  Hz,	  1H)	  6.89	  (d,	  J	  8.5	  Hz,	  2H),	  5.88	  (s,	  1H),	  3.90	  (s,	  3H);	  13C	  NMR	  (125	  MHz,	  CDCl3):	  δ	  167.4,	  160.6,	  155.7,	  155.0,	  141.3,	  132.9,	  130.5,	  129.2,	  129.1,	  128.9,	  128.5,	  128.4,	  128.3,	  127.1,	  126.9,	  126.8,	  116.8,	  115.8,	  52.9;	  IR	  (film):	  3374,	  1741,	  1612,	  1519,	  1445,	  1335,	  1221,	  1175,	  1103,	  1018,	  838,	  770,	  694	  cm-­‐1;	  LRMS	  (m/z,	  ES-­‐):	  370	  ([M	  –	   1]-­‐,	   100%);	   HRMS	   (m/z,	   ES+):	   [M	   +	   H]+	   calcd.	   for	   C23H18NO4,	   372.1231;	  found,	  372.1223.	  	  	   Following	   the	   procedure	   outlined	   for	   the	   preparation	   of	   the	   carboxylic	  acid	  1,	  methyl	  4-­‐(4ʹ′-­‐hydroxy-­‐3-­‐biphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	   (160	  mg,	  0.43	  mmol)	   in	  MeOH	  (4	  mL)	  and	  aqueous	  sodium	  hydroxide	  (2	  M,	  1.1	  mL,	  2.15	  mmol),	  after	  recrystallisation	  (light	  petroleum:EtOAc,	  100:1	  v/v),	  gave	  the	  
	  title	  compound	  6	  as	  a	  white	  solid	  (90	  mg,	  0.25	  mmol,	  59%);	  mp:	  186.0-­‐187.3	  oC;	  TLC	  (light	  petroleum:EtOAc,	  50:50	  v/v	  with	  0.1%	  TFA):	  Rf	  =	  0.49;	  HPLC	  (silica,	  EtOAc	   with	   0.1	  %	   TFA):	   retention	   time	   3.23	  min,	   100	  %;	   1H	   NMR	   (400	  MHz,	  DMSO-­‐d6):	  δ	  13.99	  (br.	  s,	  1H),	  9.60	  (s,	  1H),	  7.67-­‐7.41	  (m,	  10H),	  7.25	  (d,	  J	  7.5	  Hz,	  1H),	  6.83	  (d,	  J	  8.5	  Hz,	  2H);	  13C	  NMR	  (100	  MHz,	  DMSO-­‐d6):	  δ	  166.2,	  161.1,	  157.4,	  156.3,	  140.4,	  130.7,	  130.2,	  129.4,	  129.2,	  129.1,	  128.0,	  127.8,	  127.6,	  126.8,	  126.5,	  126.0,	  116.2,	  115.8;	  IR	  (film):	  3058,	  1754,	  1655,	  1612,	  1545,	  1512,	  1441,	  1222,	  1177,	  836,	  803,	  760	  cm-­‐1.	  	  
4-­‐(3ʹ′-­‐Hydroxy-­‐3-­‐biphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylic	  acid	  (7)	  Following	   the	   procedure	   outlined	   for	   the	   preparation	   of	   the	   methyl	   4-­‐biphenylisoxazole-­‐3-­‐carboxylate	  22,	  the	  aryl	  triflate	  19	  (300	  mg,	  0.7	  mmol)	  and	  3-­‐hydroxyphenylboronic	  acid	  (107	  mg,	  0.77	  mmol)	  in	  DMF	  (7	  mL)	  together	  with	  Pd(PPh3)4	   (8	   mg,	   0.007	   mmol),	   after	   repeated	   chromatography	   (Et2O:light	  petroleum,	   20:80	   –	   40:60	   v/v,	   then	   with	   DCM)	   gave	   methyl	   4-­‐(3ʹ′-­‐hydroxy-­‐3-­‐biphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	  as	  a	  white	  solid	  (50	  mg,	  0.135	  mmol,	  19%);	   mp:	   59.0-­‐59.6	   oC;	   TLC	   (Et2O:light	   petroleum,	   40:60	   v/v):	   Rf	   =	   0.14;	   1H	  NMR	  (300	  MHz,	  CDCl3):	  δ	  7.54	  (dt,	  J	  2.0,	  8.0	  Hz,	  1H),	  7.48-­‐7.44	  (m,	  3H),	  7.38	  (t,	  J	  8.0	  Hz,	  1H),	  7.29-­‐7.14	  (m,	  5H),	  7.05-­‐6.85	  (m,	  2H),	  6.73	  (ddd,	  J	  1.0,	  3.5,	  8.0	  Hz,	  1H),	  5.92	  (s,	  1H),	  3.76	  (s,	  3H);	  13C	  NMR	  (100	  MHz,	  CDCl3):	  δ	  167.4,	  160.4,	  156.1,	  154.8,	  141.9,	  141.1,	  130.5,	  129.9,	  129.2,	  129.1,	  129.0,	  128.9,	  128.8,	  127.3,	  127.0,	  126.6,	  119.3,	  116.6,	  114.6,	  114.1,	  52.8;	   IR	  (film):	  3393,	  1741,	  1597,	  1445,	  1332,	  1220,	  783,	  694	  cm-­‐1;	  LRMS	  (m/z,	  ES-­‐):	  370	  ([M	  –	  1]-­‐,	  80%);	  HRMS	  (m/z,	  ES+):	  [M	  +	  H]+	  calcd.	  for	  	  C23H18NO4,	  372.1231;	  found,	  372.1238.	  	  
	  	   Following	   the	   procedure	   outlined	   for	   the	   preparation	   of	   the	   carboxylic	  acid	   1,	   methyl	   4-­‐(3ʹ′-­‐hydroxy-­‐3-­‐biphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	   (50	  mg,	  0.135	  mmol)	  in	  MeOH	  (2	  mL)	  and	  aqueous	  sodium	  hydroxide	  (2	  M,	  1.1	  mL,	  2.15	  mmol),	  after	  recrystallisation	  (light	  petroleum:EtOAc,	  100:1	  v/v),	  gave	  the	  
title	  compound	  7	  as	  a	  white	  solid	  (40	  mg,	  0.11	  mmol,	  82%);	  mp:	  189.9-­‐190.8	  oC;	  TLC	  (light	  petroleum:EtOAc,	  50:50	  v/v	  with	  0.1%	  TFA):	  Rf	  =	  0.49;	  HPLC	  (silica,	  EtOAc	   with	   0.1	  %	   TFA):	   retention	   time	   3.22	  min,	   100	  %;	   1H	   NMR	   (400	  MHz,	  DMSO-­‐d6):	  δ	  14.02	  (br.	  s,	  1H),	  9.55	  (s,	  1H),	  7.66	  (ddd,	  J	  1.5,	  2.0,	  8.0	  Hz,	  1H),	  7.61	  (dd,	  J	  1.5,	  2.0	  Hz,	  1H),	  7.52-­‐7.42	  (m,	  6H),	  7.33	  (dt,	  J	  1.5,	  7.5	  Hz,	  1H),	  7.23	  (t,	  J	  8.0	  Hz,	  1H),	  7.03	  (d,	  J	  8.0	  Hz,	  1H),	  6.99	  (t,	  J	  2.0	  Hz,	  1H),	  6.76	  (dd,	  J	  2.0,	  8.0	  Hz,	  1H);	  	  13C	  NMR	   (100	   MHz,	   DMSO-­‐d6):	   δ	   171.8,	   163.1,	   157.8,	   157.6,	   157.8,	   157.6,	   140.9,	  140.4,	  130.7,	  130.0,	  129.8,	  129.2,	  129.1,	  129.0,	  128.2,	  126.8,	  126.6,	  117.4,	  114.7,	  113.5;	   IR	   (film):	  3066,	  1736,	  1598,	  1489,	  1458,	  1429,	  1349,	  1322,	  1240,	  1210,	  1023,	  992,	  896,	  866,	  810,	  785,	  764,	  719	  cm-­‐1;	  LRMS	  (m/z,	  ES-­‐):	  312	   ([M	  –	  45]-­‐,	  100%);	   HRMS	   (m/z,	   ES-­‐):	   [M	   –	   CO2H]-­‐	   calcd.	   for	   C21H14NO2,	   312.1030;	   found,	  312.1017.	  	  
4-­‐(3ʹ′ ,5ʹ′-­‐Dichoro-­‐3-­‐biphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylic	  acid	  (8)	  Following	   the	   procedure	   outlined	   for	   the	   preparation	   of	   the	   methyl	   4-­‐biphenylisoxazole-­‐3-­‐carboxylate	  22,	  the	  aryl	  triflate	  19	  (290	  mg,	  0.68	  mmol)	  and	  3,5-­‐dichlorophenylboronic	   acid	   (143	  mg,	   0.75	  mmol)	   in	   DMF	   (7	  mL)	   together	  with	  Pd(PPh3)4	  (8	  mg,	  0.007	  mmol),	  after	  repeated	  chromatography	  (Et2O:light	  petroleum,	  20:80	  –	  40:60	  v/v,	   then	  with	  DCM),	  gave	  methyl	  4-­‐(3ʹ′,5ʹ′-­‐dichoro-­‐3-­‐biphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	  as	  a	  white	  solid	  (120	  mg,	  0.28	  mmol,	  42%);	   TLC	   (Et2O:light	   petroleum,	   40:60	   v/v):	   Rf	   =	   0.51;	   1H	   NMR	   (500	   MHz,	  
	  CDCl3):	  δ	  7.52	  (d,	   J	  7.5	  Hz,	  1H),	  7.45-­‐7.42	  (m,	  4H),	  7.34-­‐7.30	  (m,	  4H),	  7.27-­‐7.23	  (m,	  3H),	   3.82	   (s,	   3H);	   13C	  NMR	   (125	  MHz,	  CDCl3):	   δ	  167.4,	   160.3,	   154.7,	   143.3,	  138.9,	  135.2,	  130.5,	  130.2,	  129.7,	  129.4,	  128.9,	  128.8,	  127.4,	  127.0,	  126.6,	  125.6,	  116.1,	   52.8;	   IR	   (film):	   3074,	   1740,	   1585,	   1560,	   1444,	   1334,	   1220,	   1175,	   1100,	  1028,	  973,	  857,	  794,	  770,	  693	  cm-­‐1.	  	  	   Following	   the	   procedure	   outlined	   for	   the	   preparation	   of	   the	   carboxylic	  acid	  1,	  methyl	  4-­‐(3ʹ′,5ʹ′-­‐chloro-­‐3-­‐biphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	  (120	  mg,	  0.28	  mmol)	  in	  MeOH	  (3	  mL)	  and	  aqueous	  sodium	  hydroxide	  (2	  M,	  1	  mL,	  2.15	  mmol),	   after	   recrystallisation	   (light	   petroleum:EtOA,	   100:1	   v/v),	   gave	   the	   title	  
compound	  8	  as	  a	  white	  solid	  (55	  mg,	  0.13	  mmol,	  48%);	  mp:	  169.9-­‐171.0	  oC;	  TLC	  	  (light	  petroleum:EtOAc,	  50:50	  v/v	  with	  0.1%	  TFA):	  Rf	  =	  0.53;	  HPLC	  (silica,	  EtOAc	  with	  0.1	  %	  TFA):	  retention	  time	  4.29	  min,	  100	  %;	  1H	  NMR	  (400	  MHz,	  DMSO-­‐d6):	  δ	  14.00	  (br.	  s,	  1H),	  7.85-­‐7.81	  (m,	  2H),	  7.74	  (d,	  J	  2.0	  Hz,	  2H),	  7.60	  (m,	  1H),	  7.55-­‐7.39	  (m,	  7H);	  13C	  NMR	  (100	  MHz,	  DMSO-­‐d6):	  δ	  160.9,	  156.1,	  143.0,	  139.3,	  137.2,	  134.7,	  130.7,	  129.8,	  129.3,	  129.1,	  128.9,	  127.1,	  127.0,	  126.9,	  126.5,	  125.5,	  125.4,	  115.9;	   IR	   (film):	  3072,	  1716,	  1587,	  1559,	  1484,	  1442,	  1374,	  1274,	  1229,	  1192,	  1026,	  987,	  918,	  856,	  770,	  720,	  692	  cm-­‐1.	  	  
4-­‐(3ʹ′ ,5ʹ′-­‐Dimethyl-­‐4ʹ′-­‐hydroxy-­‐3-­‐biphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylic	  
acid	  (9)	  Following	   the	   procedure	   outlined	   for	   the	   preparation	   of	   the	   methyl	   4-­‐biphenylisoxazole-­‐3-­‐carboxylate	  22,	  the	  aryl	  triflate	  19	  (290	  mg,	  0.68	  mmol)	  and	  3,5-­‐dimethyl-­‐4-­‐hydroxyphenylboronic	  acid	  (185	  mg,	  0.75	  mmol)	  in	  DMF	  (7	  mL)	  together	   with	   Pd(PPh3)4	   (8	   mg,	   0.007	   mmol),	   after	   repeated	   chromatography	  (Et2O:light	  petroleum,	  20:80	  –	  40:60	  v/v,	  then	  with	  DCM),	  gave	  methyl	  4-­‐(3ʹ′,5ʹ′-­‐
	  dimethyl-­‐4ʹ′-­‐hydroxy-­‐3-­‐biphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	   as	   a	   white	  solid	   (154	   mg,	   0.39	   mmol,	   57%);	   TLC	   (Et2O:light	   petroleum,	   40:60	   v/v):	   Rf	   =	  0.20;	   1H	  NMR	  (500	  MHz,	  CDCl3):	  δ	  7.69	   (d,	   J	  7.5	  Hz,	  1H),	  7.66	   (d,	   J	  8.0	  Hz,	  2H),	  7.60	  (s,	  1H),	  7.55	  (t,	  J	  8.0	  Hz,	  1H),	  7.48	  (t,	  J	  7.0	  Hz,	  1H),	  7.43	  (t,	  J	  8.0	  Hz,	  2H),	  7.36	  (d,	  J	  8.0	  Hz,	  1H),	  7.27	  (s,	  2H),	  4.87	  (s,	  1H),	  3.98	  (s,	  3H),	  2.37	  (s,	  6H);	  13C	  NMR	  (125	  MHz,	   CDCl3):	   δ	   167.3,	   160.5,	   155.0,	   152.1,	   141.5,	   132.5,	   130.4,	   129.2,	   129.0,	  128.8,	  128.5,	  128.3,	  127.4,	  127.1,	  126.9,	  123.4,	  116.8,	  52.8,	  16.1;	  IR	  (film):	  3513,	  2954,	  1741,	  1603,	  1444,	  1325,	  1221,	  1102,	  1034,	  974,	  874,	  816,	  794,	  769,	  703	  cm-­‐1.	  
	  	   Following	   the	   procedure	   outlined	   for	   the	   preparation	   of	   the	   carboxylic	  acid	   1,	   methyl	   4-­‐(3ʹ′,5ʹ′-­‐dimethyl-­‐4ʹ′-­‐hydroxy-­‐3-­‐biphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	   (150	   mg,	   0.38	   mmol)	   in	   MeOH	   (4	   mL)	   and	   aqueous	   sodium	  hydroxide	   (2	  M,	   1	  mL,	   2	  mmol),	   after	   recrystallisation	   (light	   petroleum:EtOAc,	  100:1	  v/v),	  gave	  the	  title	  compound	  9	  as	  a	  white	  solid	  (79	  mg,	  0.20	  mmol,	  54%);	  mp:	  182.3-­‐182.9	  oC;	  TLC	  (light	  petroleum:EtOAc,	  50:50	  v/v	  with	  0.1%	  TFA):	  Rf	  =	  0.55;	  HPLC	  (silica,	  EtOAc	  with	  0.1	  %	  TFA):	   retention	   time	  3.80	  min,	  100	  %;	   1H	  NMR	  (400	  MHz,	  DMSO-­‐d6):	  δ	  14.01	  (br.	  s,	  1H),	  8.40	  (s,	  1H),	  7.63	  (d,	  J	  8.0	  Hz,	  1H),	  7.57	  (s,	  1H),	  7.52-­‐7.41	  (m,	  6H),	  7.24	  (d,	  J	  7.5	  Hz,	  1H),	  7.21	  (s,	  2H),	  2.19	  (s,	  6H);	  13C	  NMR	   (100	   MHz,	   DMSO-­‐d6):	   δ	   163.6,	   161.1,	   153.3,	   140.6,	   130.6,	   130.3,	   129.3,	  129.1,	  129.0,	  127.8,	  127.6,	  126.8,	  126.6,	  126.0,	  124.7,	  124.5,	  116.3,	  113.2,	  16.8;	  IR	  (film):	  3474,	  1713,	  1601,	  1490,	  1433,	  1315,	  1227,	  1204,	  1178,	  1031,	  973,	  928,	  902,	  868,	  799,	  773	  cm-­‐1.	  
	  	  
	  
	  4-­‐(3ʹ′-­‐Chloro-­‐4ʹ′-­‐hydroxy-­‐3-­‐biphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylic	   acid	  
(10)	  Following	   the	   procedure	   outlined	   for	   the	   preparation	   of	   the	   methyl	   4-­‐biphenylisoxazole-­‐3-­‐carboxylate	  22,	  the	  aryl	  triflate	  19	  (300	  mg,	  0.7	  mmol)	  and	  3-­‐chloro-­‐4-­‐hydroxyphenylboronic	   acid	   (133	   mg,	   0.77	   mmol)	   in	   DMF	   (7	   mL)	  together	   with	   Pd(PPh3)4	   (8	   mg,	   0.007	   mmol),	   after	   repeated	   chromatography	  (Et2O:light	   petroleum,	   20:80	   –	   40:60	   v/v	   then	   with	   DCM),	   gave	   methyl	   4-­‐(3ʹ′-­‐chloro-­‐4ʹ′-­‐hydroxy-­‐3-­‐biphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	  as	  a	  white	  solid	  (180	  mg,	  0.44	  mmol,	  63%);	  mp:	  60.3-­‐61.9	   oC;	  TLC	  (Et2O:light	  petroleum,	  40:60	  v/v):	  Rf	  =	  0.14;	  1H	  NMR	  (500	  MHz,	  CDCl3):	  δ	  7.60-­‐7.56	  (m,	  3H),	  7.53-­‐7.48	  (m,	  3H),	  7.43-­‐7.32	  (m,	  5H),	  7.08	  (d,	  J	  8.5	  Hz,	  1H),	  5.62	  (s,	  1H),	  3.91	  (s,	  3H);	  13C	  NMR	  (125	  MHz,	   CDCl3):	   δ	   167.4,	   160.5,	   154.9,	   151.0,	   140.0,	   134.2,	   130.5,	   129.5,	   129.2,	  129.1,	  128.9,	  128.6,	  127.6,	  127.2,	  127.1,	  126.9,	  126.8,	  120.3,	  116.6,	  116.5,	  52.8;	  IR	   (film):	   3419,	   3061,	   2955,	   1740,	   1608,	   1508,	   1485,	   1464,	   1444,	   1387,	   1335,	  1287,	  1221,	  1177,	  1102,1054,	  1021,	  973,	  909,	  867,	  816,	  794,	  770,	  731,	  706	  cm-­‐1;	  LRMS	  (m/z,	  ES-­‐):	  406	  ([M	  –	  1]-­‐,	  65%),	  404	  ([M	  –	  1]-­‐,	  100);	  HRMS	  (m/z,	  ES+):	  [M	  +	  H]+	  calcd.	  for	  C23H17NO4	  35Cl,	  406.0841;	  found,	  406.0845.	  	   Following	   the	   procedure	   outlined	   for	   the	   preparation	   of	   the	   carboxylic	  acid	   1,	   methyl	   4-­‐(3ʹ′-­‐chloro-­‐4ʹ′-­‐hydroxy-­‐3-­‐biphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	   (157	   mg,	   0.39	   mmol)	   in	   MeOH	   (4	   mL)	   and	   aqueous	   sodium	  hydroxide	  (2	  M,	  1	  mL,	  2.15	  mmol),	  after	  recrystallisation	  (light	  petroleum:EtOAc,	  100:1	  v/v),	  gave	  the	  title	  compound	  10	  as	  a	  white	  solid	  (80	  mg,	  0.2	  mmol,	  52%	  yield);	   mp:	   171.8-­‐175.0	   oC;	   TLC	   (light	   petroleum:EtOAc,	   50:50	   v/v	   with	   0.1%	  TFA):	  Rf	  =	  0.5;	  HPLC	  (silica,	  EtOAc	  with	  0.1	  %	  TFA):	  retention	  time	  3.20	  min,	  100	  %;	  1H	  NMR	  (400	  MHz,	  DMSO-­‐d6):	  δ	  14.00	  (br.	  s,	  1H),	  10.38	  (s,	  1H),	  7.68-­‐7.62	  (m,	  
	  3H),	  7.51-­‐7.41	  (m,	  7H),	  7.28	  (d,	  J	  7.5	  Hz,	  1H),	  7.03	  (d,	  J	  8.5	  Hz,	  1H);	  13C	  NMR	  (100	  MHz,	  DMSO-­‐d6):	   δ	  166.2,	  161.0,	  156.3,	  152.9,	  138.9,	  131.5,	  130.7,	  129.5,	  129.2,	  129.1,	   128.6,	   127.9,	   127.8,	   126.9,	   126.5,	   126.3,	   126.1,	   120.3,	   117.0,	   116.1;	   IR	  (film):	  3361,	  1712,	  1607,	  1483,	  1425,	  1343,	  1279,	  1229,	  1142,	  1059,	  930,	  882,	  866,	  820,	  802,	  788,	  771	  cm-­‐1.	  	  
4-­‐(3ʹ′-­‐Fluoro-­‐4ʹ′-­‐hydroxy-­‐3-­‐biphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylic	   acid	  
(11)	  Following	   the	   procedure	   outlined	   for	   the	   preparation	   of	   the	   methyl	   4-­‐biphenylisoxazole-­‐3-­‐carboxylate	  22,	  the	  aryl	  triflate	  19	  (630	  mg,	  1.45	  mmol)	  and	  3-­‐fluoro-­‐4-­‐hydroxyphenylboronic	  acid	  (250	  mg,	  1.6	  mmol)	  in	  DMF	  (15	  mL)	  with	  Pd(PPh3)4	   (15	   mg,	   0.014	   mmol),	   after	   repeated	   chromatography	   (Et2O:light	  petroleum,	   20:80	   –	   40:60	   v/v,	   then	   with	   DCM)	   gave	   methyl	   4-­‐(3ʹ′-­‐fluoro-­‐4ʹ′-­‐hydroxy-­‐3-­‐biphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	  as	  a	  white	  solid	  (260	  mg,	  0.67	  mmol,	  42%);	  mp:	  63.4-­‐65.0	  oC;	  TLC	  (Et2O:light	  petroleum,	  30:70	  v/v):	  Rf	  =	  0.12;	  1H	  NMR	  (400	  MHz,	  CDCl3):	  δ	  7.49-­‐7.37	  (m,	  5H),	  7.32-­‐7.11	  (m,	  6H),	  6.92	  (t,	  J	  8.5	  Hz,	  1H),	  5.81	  (s,	  1H),	  3.80	  (s,	  3H);	  13C	  NMR	  (100	  MHz,	  CDCl3):	  δ	  167.5,	  160.6,	  154.9,	  152.5,	  150.1,	  143.3,	  140.2,	  133.5,	  130.6,	  129.4,	  129.3,	  129.0,	  128.5,	  127.1,	  127.0,	  126.8,	  123.3,	  117.7,	  116.7,	  114.4,	  52.9;	  IR	  (film):	  3363,	  3059,	  2955,	  1737,	  1621,	  1522,	  1444,	  1215,	  1104,	  1021,	  973,	  868,	  815,	  789,	  768,	  749,	  691	  cm-­‐1.	  
	   Following	   the	   procedure	   outlined	   for	   the	   preparation	   of	   the	   carboxylic	  acid	   1,	   methyl	   4-­‐(3ʹ′-­‐fluoro-­‐4ʹ′-­‐hydroxy-­‐3-­‐biphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	   (70	   mg,	   0.18	   mmol)	   in	   MeOH	   (1.5	   mL)	   and	   aqueous	   sodium	  hydroxide	   (2	   M,	   0.5	   mL,	   1.0	   mmol),	   after	   recrystallisation	   (light	  petroleum:EtOAc,	  100:1	  v/v),	  gave	  the	  title	  compound	  11	  as	  a	  white	  solid	  (10	  mg,	  
	  0.03	  mmol,	   17%);	  mp:	   193.5-­‐194.6	   oC;	   TLC	   (light	   petroleum:EtOAc,	   50:50	   v/v	  with	  0.1%	  TFA):	  Rf	  =	  0.09;	  HPLC	  (silica,	  EtOAc	  with	  0.1	  %	  TFA):	  retention	  time	  3.17	  min,	  100	  %;	  1H	  NMR	  (500	  MHz,	  DMSO-­‐d6):	  δ	  13.99	  (br.	  s,	  1H),	  10.03	  (s,	  1H),	  7.69-­‐7.66	  (m,	  2H),	  7.52-­‐7.42	  (m,	  7H),	  7.31	  (d,	  J	  8.0	  Hz,	  1H),	  7.28	  (d,	  J	  7.5	  Hz,	  1H),	  7.00	  (t,	  J	  9.0	  Hz,	  1H);	  IR	  (film):	  3261,	  1719,	  1621,	  1522,	  1443,	  1216,	  1118,	  871,	  796,	  751,	  691	  cm-­‐1.	  	  
4-­‐(3ʹ′-­‐Chloro-­‐4ʹ′-­‐hydroxy-­‐5ʹ′-­‐nitro-­‐3-­‐biphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐
carboxylic	  acid	  (12)	  A	  mixture	   of	   4-­‐bromo-­‐2-­‐chloro-­‐6-­‐nitrophenol	   (1	   g,	   3.96	  mmol),	   KOAc	   (1.17	   g,	  11.88	   mmol),	   bis(pinacolato)diboron	   (1.21	   g,	   4.75	   mmol)	   and	   [1,1ʹ′-­‐bis(diphenylphosphino)ferrocene]palladium(II)	   	   dichloride	   (90	   mg,	   0.1188	  mmol)	   in	  dioxane	  (40	  mL)	  was	  stirred	  under	  nitrogen	  at	  90	   oC	   for	  18	  h	  before	  being	   poured	   into	   EtOAc	   (100	   mL).	   The	   mixture	   was	   washed	   with	   aqueous	  hydrogen	   chloride	   (1	   M,	   100	   mL),	   dried	   (MgSO4)	   and	   concentrated	   under	  reduced	  pressure.	  Chromatography	  (Et2O:light	  petroleum,	  5:95	  –	  10:90	  	  v/v)	  of	  the	  residue	  gave	  pinacolyl	  3-­‐chloro-­‐4-­‐hydroxy-­‐5-­‐nitrophenylboronate	  as	  a	  bright	  yellow	  solid	  (0.46	  g,	  1.54	  mmol,	  39%);	  TLC	  	  (Et2O:light	  petroleum,	  20:80,	  v/v):	  Rf	  =	  0.69.	  The	  crude	  product	  was	  used	  in	  the	  next	  reaction.	  	   Following	   the	   procedure	   outlined	   for	   the	   preparation	   of	   the	   methyl	   4-­‐biphenylisoxazole-­‐3-­‐carboxylate	  22,	  the	  aryl	  triflate	  19	  (295	  mg,	  0.69	  mmol)	  and	  pinacolyl	   3-­‐chloro-­‐4-­‐hydroxy-­‐5-­‐nitrophenylboronate	   (310	   mg,	   1.04	   mmol)	   in	  DMF	  (7	  mL)	  with	  Pd(PPh3)4	  (8	  mg,	  0.007	  mmol),	  after	  repeated	  chromatography	  (Et2O:light	   petroleum,	   20:80	   –	   40:60	   v/v	   then	   with	   DCM),	   gave	   methyl	   4-­‐(3ʹ′-­‐chloro-­‐4ʹ′-­‐hydroxy-­‐5ʹ′-­‐nitro-­‐3-­‐biphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	   as	   a	  
	  white	   solid	   (45	   mg,	   0.103	   mmol,	   15%);	   mp:	   74.5-­‐75.7	   oC;	   TLC	   (Et2O:light	  petroleum,	  30:70	  v/v):	  Rf	  =	  0.49;	  1H	  NMR	  (400	  MHz,	  CDCl3):	  δ	  11.00	  (s,	  1H),	  8.23	  (d,	  J	  2.5	  Hz,	  1H),	  7.91	  (d,	  J	  2.5	  Hz,	  1H),	  7.62	  (m,	  1H),	  7.58-­‐7.54	  (m,	  4H),	  7.43	  (d,	  J	  7.5	  Hz,	   2H),	   7.37	   (d,	   J	  7.5	  Hz,	   2H),	   3.93	   (s,	   3H);	   13C	   NMR	   (100	  MHz,	   CDCl3):	   δ	  167.6,	  160.4,	  154.7,	  150.7,	  137.7,	  136.2,	  134.6,	  132.8,	  130.7,	  130.4,	  130.0,	  129.7,	  128.9,	  128.7,	  127.1,	  126.9,	  126.6,	  125.1,	  121.6,	  116.1,	  52.9;	  IR	  (film):	  3223,	  3078,	  2948,	  1737,	  1621,	  1539,	  1218,	  1173,	  1110,	  1029,	  815,	  692	  cm-­‐1.	  
	  	   Following	   the	   procedure	   outlined	   for	   the	   preparation	   of	   the	   carboxylic	  acid	  1,	  methyl	  4-­‐(3ʹ′-­‐chloro-­‐4ʹ′-­‐hydroxy-­‐5ʹ′-­‐nitrobiphenyl-­‐3-­‐yl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	   (45	   mg,	   0.1	   mmol)	   in	   MeOH	   (1	   mL)	   and	   aqueous	   sodium	  hydroxide	  (2	  M,	  0.25	  mL,	  2	  mmol),	  after	  recrystallisation	  (light	  petroleum:EtOAc,	  100:1	  v/v),	  gave	  the	  title	  compound	  12	  as	  a	  white	  solid	  (20	  mg,	  0.05	  mmol,	  46%);	  mp:	  185.4-­‐185.9	  oC;	  TLC	  (light	  petroleum:EtOAc,	  50:50	  v/v	  with	  0.1%	  TFA):	  Rf	  =	  0.15;	  HPLC	  (silica,	  EtOAc	  with	  0.1	  %	  TFA):	   retention	   time	  3.08	  min,	  100	  %;	   1H	  NMR	   (500	  MHz,	  DMSO-­‐d6):	   δ	   13.97	   (br.	   s,	   1H),	   11.30	   (br.	   s,	   1H),	   8.16	   (m,	   1H),	  8.14	  (m,	  1H),	  7.84-­‐7.80	  (m,	  2H),	  7.54-­‐7.41	  (m,	  6H),	  7.37	  (dd,	  J	  1.0,	  8.0	  Hz,	  1H);	  13C	  NMR	   (125	   MHz,	   DMSO-­‐d6):	   δ	   166.3,	   160.9,	   156.2,	   147.5,	   138.6,	   136.7,	   133.1,	  131.1,	  130.6,	  129.8,	  129.7,	  129.3,	  129.1,	  128.3,	  126.8,	  126.4,	  124.6,	  121.4,	  116.0;	  IR	  (film):	  3256,	  3061,	  2900,	  1716,	  1619,	  1538,	  1429,	  1319,	  1229,	  1110,	  906,	  795,	  763,	  691	  cm-­‐1.	  	  
4-­‐(3',5'-­‐Dichloro-­‐4'-­‐hydroxy-­‐3-­‐biphenyl)-­‐5-­‐methylisoxazole-­‐3-­‐carboxylic	  
acid	  (13)	  Trifluoromethanesulfonic	  anhydride	  (2.18	  g,	  7.72	  mmol)	  was	  added	  to	  methyl	  4-­‐(3-­‐hydroxyphenyl)-­‐5-­‐methylisoxazole-­‐3-­‐carboxylate	  (25)	  (1.2	  g,	  5.15	  mmol)	  and	  
	  pyridine	   (1.01	   g,	   12.87	   mmol)	   in	   dichloromethane	   (30	   mL)	   at	   0	   oC	   and	   the	  reaction	  mixture	  was	  stirred	  at	  rt	   for	  6	  h	   then	  poured	   into	  water	  (30	  mL).	  The	  mixture	   was	   extracted	   with	   dichloromethane	   (2	   ×	   50	   ml)	   and	   the	   organic	  extracts	   were	   dried	   (NaSO4)	   and	   concentrated	   under	   reduced	   pressure.	  Chromatography	   of	   the	   residue	   (EtOAc:light	   petroleum,	   20:80	   v/v)	   gave	   the	  triflate	  26	  as	  an	  off-­‐white	  solid	  (1.2	  g,	  66%);	  TLC	  (EtOAc:light	  petroleum,	  10:90	  v/v):	  Rf	  =	  0.8;	  1H	  NMR	  (400	  MHz,	  CDCl3):	  δ	  7.45	  (m,	  1H),	  7.40-­‐7.10	  (m,	  3H),	  3.90	  (s,	  3H)	  2.45	  (s,	  3H);	  LRMS	  (m/z,	  ES+):	  306	  ([M	  -­‐	  59]+,	  100%).	  
	   Sodium	  carbonate	  in	  water	  (1.3	  g,	  12.3	  mmol	  in	  1	  mL	  water)	  was	  added	  to	  a	   solution	   of	   methyl	   5-­‐methyl-­‐4-­‐(3-­‐trifluoromethanesulfonyloxyphenyl)-­‐isoxazole-­‐3-­‐carboxylate	   (26)	   (1.5	   g,	   4.10	  mmol)	   and	   pinacolyl	   (3,5-­‐dichloro-­‐4-­‐hydroxyphenyl)boronate	   (21)	   (1.77	  g,	  6.16	  mmol)	   in	  DMF	  (10	  mL)	  at	  0	   oC	  and	  the	  reaction	  mixture	  was	  degassed	  by	  bubbling	  nitrogen	  through	  for	  15	  min.	  	  The	  catalyst	  Pd(PPh3)4	  (470	  mg,	  0.04	  mmol)	  was	  added	  and	  the	  mixture	  heated	  to	  90	  
oC	  for	  3	  h	  then	  cooled	  to	  rt	  and	  poured	  into	  ice-­‐water	  (10	  mL).	  The	  mixture	  was	  extracted	  with	  EtOAc	  (2	  ×	  20	  mL)	  and	  the	  organic	  extracts	  were	  dried	  (NaSO4)	  and	  concentrated	  under	  reduced	  pressure	  to	  afford	  the	  methyl	  4-­‐(3ʹ′,5ʹ′-­‐dichloro-­‐4ʹ′-­‐hydroxy-­‐3-­‐biphenyl)-­‐5-­‐methylisoxazole-­‐3-­‐carboxylate	   (27)	   as	   an	   off-­‐white	  solid	  (1.5	  g)	  used	  without	  purification;	  TLC	  (EtOAc:light	  petroleum,	  5:95	  v/v):	  Rf	  =	  0.5;	  LRMS	  (m/z,	  ES-­‐)	  376	  ([M(Cl35)2	  -­‐	  1]-­‐,	  100%),	  378	  ([M(Cl35Cl37)	  -­‐	  1]-­‐,	  65%),	  380	  ([M(Cl37)2	  -­‐	  1]-­‐,	  10%).	  	  	   Aqueous	  sodium	  hydroxide	  (152	  mg	  in	  1	  mL	  water,	  3.8	  mmol)	  was	  added	  to	  the	  methyl	  ester	  27	  (500	  mg,	  1.19	  mmol)	  in	  MeOH:THF	  (12	  mL,	  3:1	  v/v)	  at	  0	  
oC	  and	  the	  mixture	  stirred	  for	  1	  h	  at	  0	  oC	  then	  poured	  into	  ice-­‐water	  (5	  mL).	  The	  mixture	  was	  acidified	   to	  pH~1	  using	   aqueous	  hydrochlogen	  chloride	   (2M)	  and	  
	  concentrated	  under	  reduced	  pressure	  to	  give	  aqueous	  slurry	  that	  was	  extracted	  with	   EtOAc	   (3	   ×	   10	   mL).	   The	   organic	   extracts	   were	   dried	   (NaSO4)	   and	  concentrated	   under	   reduced	   pressure	   to	   give	   an	   off-­‐white	   solid	   that	   was	  crystallized	   (light	   petroleum:EtOAc,	   90:10	   v/v)	   to	   give	   the	   title	   compound	  13	  (315	  mg,	  65%)	  as	  an	  off-­‐white	  solid;	  TLC	  (MeOH:dichloromethane,	  10:90	  v/v):	  Rf	  =	  0.2;	  1H	  NMR	  (400	  MHz,	  DMSO-­‐d6):	  δ	  13.87	  (br.	  s,	  1H),	  10.27	  (s,	  1H),	  7.75-­‐7.60	  (m,	  4H),	  7.50	  (t,	  J	  7.6	  Hz,	  1H),	  7.34	  (d,	  J	  7.6	  Hz,	  1H),	  2.47	  (s,	  3H);	  13C	  NMR	  (100	  MHz,	  DMSO-­‐d6):	   δ	  168.6,	  162.0,	  155.4,	  149.1,	  137.9,	  133.1,	  130.0,	  129.4,	  129.2,	  128.1,	  127.1,	  126.3,	  123.3,	  116.5	  and	  11.8;	  	  LRMS	  (m/z,	  ES+)	  364	  ([M(Cl35)2	  +	  1]+,	  100%),	  366	  ([M(Cl35Cl37)	  +	  1]+,	  50%),	  368	  ([M(Cl37)2	  +	  1]+,	  10%).	  	  
Methyl	  5-­‐phenylisoxazole-­‐3-­‐carboxylate	  (14)	  20	  21	  Sodium	   methoxide	   (18.36	   g,	   340	   mmol)	   in	   MeOH	   (80	   mL)	   was	   added	   to	  acetophenone	   (20	   mL,	   161.92	   mmol)	   and	   dimethyl	   oxalate	   (28.66	   g,	   242.9	  mmol)	  in	  MeOH	  (450	  mL)	  at	  rt	  and	  the	  solution	  was	  stirred	  at	  rt	  for	  2	  h	  before	  being	   cooled	   to	   rt	   and	  poured	   into	   aqueous	  hydrogen	   chloride	   (2	  M,	   800	  mL).	  The	   solid	   methyl	   2,4-­‐dioxo-­‐4-­‐phenylbutanoate	   was	   filtered	   off,	   washed	   with	  water	  and	  used	  the	  next	  step	  without	  further	  purification.	  	   Hydroxylamine	   hydrochloride	   (10.8	   g,	   154.6	   mmol)	   was	   added	   to	   the	  methyl	  2,4-­‐dioxo-­‐4-­‐phenylbutanoate	  (21.37	  g,	  103	  mmol)	  in	  MeOH	  (520	  mL)	  and	  the	  mixture	  was	  stirred	  under	  reflux	  for	  24	  hours.	  After	  cooling	  to	  rt,	  the	  mixture	  was	   poured	   into	   water	   (1	   L)	   and	   cooled	   to	   0	   oC.	   The	   white	   precipitate	   was	  filtered	  off,	  washed	  with	  water,	   and	   then	  dissolved	   in	  EtOAc.	  The	   solution	  was	  dried	   (MgSO4)	   and	   concentrated	   under	   reduced	   pressure	   to	   give	   the	   title	  compound	  14	  as	  a	  white	  solid	  (18.4	  g,	  90.6	  mmol,	  88%);	  mp:	  81.8	  –	  82.5	  oC	  (lit.	  21	  
	  80-­‐82	   oC);	   TLC	   (Et2O:light	   petroleum,	   10:90	   v/v):	   Rf	   =	   0.2;	   1H	  NMR	   (300	  MHz,	  DMSO-­‐d6):	  δ	  7.98-­‐7.92	  (m,	  2H),	  7.57-­‐7.52	  (m,	  3H),	  7.51	  (s,	  1H),	  3.92	  (s,	  3H);	  13C	  NMR	  (75	  MHz,	  DMSO-­‐d6):δ171.1,	  159.8,	  156.6,	  131.0,	  129.3,	  126.0,	  125.8,	  100.8,	  52.8;	   IR	   (film):	   3130,	   2951,	   1724,	   1612,	   1591,	   1571,	   1445,	   1425,	   1246,	   1141,	  1004,	  946,	  934,	  920,	  851,	  837,	  807,	  781,	  764	  cm-­‐1.	  	  
Methyl	  4-­‐bromo-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	  (15)	  22	  
N-­‐Bromosuccinimide	   (6.85	   g,	   38.47	   mmol)	   was	   added	   to	   methyl	   5-­‐phenylisoxazole-­‐3-­‐carboxylate	   14	   (7.1	   g,	   34.98	   mmol)	   in	   trifluoroacetic	   acid	  (100	  mL)	  and	  solution	  stirred	  under	  reflux	  for	  48	  h	  before	  being	  cooled	  to	  rt	  and	  poured	  onto	   ice.	  The	  white	  precipitate	  was	   filtered	  off	   and	   recrystallised	   (light	  petroleum:EtOAc,	   100:1	   v/v)	   to	   give	   the	   title	   compound	   15	   as	   white	   crystals	  (6.35	   g,	   22.5	   mmol,	   64%);	   mp:	   108-­‐110	   oC	   (lit.	   22	   66-­‐68	   oC);	   TLC	   (Et2O:light	  petroleum,	  10:90	  v/v):	  Rf	  =	  0.23;	  1H	  NMR	  (400	  MHz,	  DMSO-­‐d6):	  δ	  8.02-­‐7.98	  (m,	  2H),	   7.65-­‐7.60	   (m,	   3H),	   3.94	   (s,	   3H);	   13C	   NMR	   (100	  MHz,	   DMSO-­‐d6):	  δ	  167.2,	  158.9,	  154.6,	  131.8,	  129.5,	  127.1,	  125.4,	  90.1,	  53.3;	  IR	  (film):	  1732,	  1565,	  1436,	  1414,	   1252,	   1215,	   1183,	   1046,	   970,	   810,	   785,	   771	   cm-­‐1;	   LRMS	   (ES+,	  m/z):	   306	  ([M	   +	   23]+,	   100%),	   304	   ([M	   +	   23]+,	   90%);	   HRMS	   (m/z):	   [M	   +	   H]+	   calcd.	   for	  C11H9NO379Br,	  	  281.9761;	  found,	  281.9759.	  	  	  
Methyl	  4,5-­‐diphenylisoxazole-­‐3-­‐carboxylate	  (16)	  23	  A	  solution	  of	  methyl	  4-­‐bromo-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	  15	  (100	  mg,	  0.35	  mmol)	  and	  phenylboronic	  acid	  (52	  mg,	  0.42	  mmol)	  in	  DMF	  (4	  mL)	  was	  degassed	  by	  bubbling	  nitrogen	  through	  it	  for	  30	  min.	  Aqueous	  sodium	  carbonate	  (2	  M,	  0.5	  
	  mL,	  1.0	  mmol)	  was	  added	  and	  nitrogen	  was	  bubbled	  through	  the	  mixture	   for	  a	  further	   15	   min.	   Bis(triphenylphosphine)palladium(II)	   dichloride	   (12	   mg,	   0.02	  mmol)	  was	  added	  and	  the	  mixture	  stirred	  at	  90	  oC	  for	  3	  hours.	  The	  mixture	  was	  cooled	   to	   rt	   and	   poured	   into	   EtOAc	   (20	   mL).	   The	   mixture	   was	   washed	   with	  aqueous	  hydrogen	  chloride	  (2	  M,	  20	  mL),	  water	  (20	  mL)	  and	  brine	  (20	  mL),	  then	  dried	   (NaSO4)	   and	   concentrated	   under	   reduced	   pressure.	   Chromatography	  (Et2O:light	  petroleum,	  20:80	  –	  40:60	  v/v)	  of	  the	  residue	  gave	  the	  title	  compound	  
16	   as	   an	   off-­‐white	   solid	   (94	  mg,	   0.34	  mmol,	   80%);	   TLC	   (Et2O:light	   petroleum,	  20:80	  v/v):	  Rf	  =	  0.40;	  1H	  NMR	  (400	  MHz,	  DMSO-­‐d6):	  δ	  7.55-­‐7.41	  (m,	  10H),	  3.84	  (s,	  3H);	  13C	  NMR	  (100	  MHz,	  DMSO-­‐d6):	  δ	  166.6,	  159.9,	  155.0,	  130.8,	  130.1,	  129.1,	  128.7,	  128.6,	  128.5,	  126.8,	  126.3,	  116.5,	  52.8;	  LRMS	  (ES+,	  m/z):	  302	  ([M	  +	  23]+,	  100%),	  280	  ([M	  +	  1]+,	  10);	  HRMS	  (m/z):	  [M	  +	  H]+	  calcd.	  for	  C17H14NO3,	  280.0969;	  found,	  280.0970.	  	  
Methyl	  4-­‐(3-­‐methoxyphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	  (17)	  A	  solution	  of	  methyl	  4-­‐bromo-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	  15	   (6.68	  g,	  23.7	  mmol)	   and	  3-­‐methoxyphenylboronic	   acid	   (4.3	  g,	   28.4	  mmol)	   in	  DMF	   (230	  mL)	  was	   degassed	   by	   bubbling	   nitrogen	   through	   it	   for	   30	   min.	   Aqueous	   sodium	  carbonate	  (2	  M,	  36	  mL,	  72	  mmol)	  was	  added	  and	  nitrogen	  was	  bubbled	  through	  the	  mixture	   for	   a	   further	  15	  min.	  The	   catalyst	  Pd(PPh3)4	   (300	  mg,	  0.24	  mmol)	  was	   added	  and	   the	  mixture	  was	   stirred	   at	   90	   oC	   for	  3	  hours.	  The	  mixture	  was	  cooled	  to	  rt	  and	  poured	  into	  EtOAc	  (250	  mL).	  The	  resulting	  mixture	  was	  washed	  with	  aqueous	  hydrogen	  chloride	  (2	  M,	  250	  mL),	  water	  (250	  mL)	  and	  brine	  (250	  mL)	   then	   dried	   (NaSO4)	   and	   concentrated	   under	   reduced	   pressure.	  Chromatography	   (Et2O:light	  petroleum,	  20:80	  –	  40:60	  v/v)	  of	   the	   residue	  gave	  
	  the	  title	  compound	  17	  as	  a	  pale	  yellow	  solid	  (3.1	  g,	  9.95	  mmol,	  42%);	  mp:	  110.5-­‐111.9	   oC;	  TLC	   (Et2O:light	  petroleum,	  40:60,	  v/v):	  Rf	  =	  0.37;	   1H	  NMR	   (500	  MHz,	  CDCl3):	  	  δ	  7.46	  (d,	  J	  =	  7.0	  Hz,	  2H),	  7.32-­‐7.24	  (m,	  4H),	  6.90	  (dd,	  J	  2.5,	  8.0	  Hz,	  1H),	  6.85	  (d,	  J	  7.5	  Hz,	  1H),	  6.81	  (m,	  1H),	  3.81	  (s,	  3H),	  3.71	  (s,	  3H);	  13C	  NMR	  (125	  MHz,	  CDCl3):	  δ	  167.2,	   160.4,	   159.7,	   155.0,	   130.4,	   130.2,	   129.8,	   128.8,	   127.0,	   126.8,	  122.5,	  116.6,	  115.8,	  114.2,	  55.3,	  52.8;	   IR	   (film):	  3012,	  2956,	  2843,	  1736,	  1587,	  1420,	  1331,	  1243,	  1213,	  1164,	  1094,	  1043,	  971,	  872,	  843,	  789,	  768,	  709,	  691	  cm-­‐
1;	   LRMS	   (ES+,	  m/z):	   332	   ([M	  +	   23]+,	   100%);	   HRMS	   (m/z):	   [M	   +	   H]+	   calcd.	   for	  C18H16NO4,	  310.1074;	  found,	  310.1071.	  	  	  
Methyl	  4-­‐(3-­‐hydroxyphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	  (18)	  A	  solution	  of	  methyl	  4-­‐bromo-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	  15	   (9.3	  g,	  32.95	  mmol)	  and	  3-­‐hydroxyphenylboronic	  acid	  (5	  g,	  36.5	  mmol)	  in	  DMF	  (330	  mL)	  was	  degassed	  by	  bubbling	  nitrogen	  through	  it	  for	  1	  hour.	  Aqueous	  sodium	  carbonate	  (2	  M,	  49.4	  mL,	  98.85	  mmol)	  was	  added	  and	  nitrogen	  was	  bubbled	   through	   the	  mixture	   for	  a	   further	  15	  min.	  The	  catalyst	  Pd(PPh3)4	  (380	  mg,	  0.33	  mmol)	  was	  added	  and	  the	  mixture	  stirred	  at	  90	  oC	  for	  90	  min.	  The	  mixture	  was	  cooled	  to	  rt	  and	  poured	   into	  EtOAc	  (1	  L).	  The	  mixture	  was	  washed	  with	  aqueous	  hydrogen	  chloride	   (2	   M,	   500	   mL),	   water	   (1	   L)	   and	   brine	   (1	   L)	   then	   dried	   (NaSO4)	   and	  concentrated	  under	  reduced	  presssure.	  Repeated	  chromatography	  of	  the	  residue	  (Et2O:light	  petroleum,	  20:80	  –	  40:60	  v/v,	  then	  DCM)	  gave	  the	  title	  compound	  18	  as	   an	   off-­‐white	   solid	   (4.76	   g,	   16.1	   mmol,	   49%);	   mp:	   148.7-­‐149.9	   oC;	   TLC	  (Et2O:light	  petroleum,	  40:60	  v/v):	  Rf	  =	  0.24;	  1H	  NMR	  (400	  MHz,	  MeOD):	  δ	  7.48-­‐7.45	  (m,	  2H),	  7.38-­‐7.28	  (m,	  3H),	  7.19	  (t,	  J	  8.0	  Hz,	  1H),	  6.82	  (ddd,	  J	  1.0,	  2.5,	  8.5	  Hz,	  
	  1H),	  6.72-­‐6.70	  (m,	  2H),	  4.65	  (s,	  1H),	  3.77	  (s,	  3H);	  13C	  NMR	  (100	  MHz,	  MeOD):	  δ	  168.4,	  161.8,	  158.9,	  156.6,	  131.7,	  131.5,	  131.2,	  131.0,	  130.0,	  128.2,	  128.1,	  122.4,	  118.1,	   116.7,	   53.2;	   IR	   (film):	   3473,	   1745,	   1590,	   1449,	   1331,	   1216,	   1164,	   1094,	  1035,	  985,	  865,	  811,	  788,	  774,	  706,	  691	  cm-­‐1;	  LRMS	  (m/z,	  ES+):	  318	  ([M	  +	  23]+,	  100%);	  HRMS	  (m/z):	  [M	  +	  H]+,	  calc.	  for	  	  C17H14NO4,	  296.0918;	  found,	  296.0913.	  	  
Methyl	   5-­‐phenyl-­‐4-­‐(3-­‐trifluoromethylsulfonyloxyphenyl)isoxazole-­‐3-­‐
carboxylate	  (19)	  Trifluoromethanesulphonic	  anhydride	  (1	  M	  in	  DCM,	  16.27	  mL,	  16.27	  mmol)	  was	  added	  to	  methyl	  4-­‐(3-­‐hydroxyphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐carboxylate	  18	   (4	  g,	  13.56	  mmol)	  and	  pyridine	  (2.18	  mL,	  27.12	  mmol)	  in	  DCM	  (135	  mL)	  at	  0	  oC	  and	  the	  reaction	  mixture	  was	  stirred	  at	  rt	  for	  90	  min	  before	  being	  poured	  into	  EtOAc	  (800	  mL).	  The	  solution	  was	  washed	  with	  aqueous	  hydrogen	  chloride	  (1	  M,	  800	  mL),	  dried	  (MgSO4)	  and	  concentrated	  under	  reduced	  pressure.	  Chromatography	  (Et2O:light	  petroleum,	  20:80	  v/v)	  of	  the	  residue	  gave	  the	  title	  compound	  19	  as	  a	  white	   solid	   (5.47	   g,	   12.75	   mmol,	   94%);	   mp:	   95.0	   –	   96.7	   oC;	   TLC	   (Et2O:light	  petroleum,	  40:60	  v/v):	  Rf	  =	  0.41;	  1H	  NMR	  (400	  MHz,	  CDCl3):	  δ	  7.55	  (t,	   J	  8.0	  Hz,	  1H),	  7.49-­‐7.35	   (m,	  7H),	  7.31	   (dd,	   J	  1.5,	  2.0	  Hz,	  1H),	  3.91	   (s,	  3H);	   13C	  NMR	  (100	  MHz,	   CDCl3):	   δ	   239.2,	   168.0,	   160.2,	   154.6,	   149.5,	   131.7,	   131.0,	   130.6,	   129.1,	  127.1,	  126.2,	  123.5,	  121.6,	  114.6,	  53.0;	  IR	  (film):	  3068,	  2968,	  1738,	  1418,	  1248,	  1210,	  1128,	  971,	  917,	  897,	  815,	  771,	  686	  cm-­‐1;	  LRMS	  (m/z,	  ES+):	  450	  ([M	  +	  23]+,	  45%).	  	  	  
	  
	  
	  Pinacolyl	  (3,5-­‐dichloro-­‐4-­‐hydroxyphenyl)boronate	  (21)	  A	  mixture	   of	   4-­‐bromo-­‐2,6-­‐dichlorophenol	  20	   (7	   g,	   28.94	  mmol),	  KOAc	   (8.52	   g,	  86.8	   mmol),	   bis(pinacolato)diboron	   (8.82	   g,	   34.73	   mmol)	   and	   [1,1ʹ′-­‐bis(diphenylphosphino)ferrocene]palladium(II)	  	  dichloride	  (640	  mg,	  0.87	  mmol)	  in	  dioxane	  (300	  mL)	  was	  stirred	  under	  nitrogen	  at	  90	  oC	   for	  18	  h	  before	  being	  poured	   into	  EtOAc	  (600	  mL).	  The	  mixture	  was	  washed	  with	  aqueous	  hydrogen	  chloride	   (1	   M,	   600	   mL),	   dried	   (MgSO4)	   and	   concentrated	   under	   reduced	  pressure.	  Chromatography	  (Et2O:light	  petroleum,	  10:90	  v/v)	  of	  the	  residue	  gave	  the	  title	  compound	  21	  as	  a	  pale	  yellow	  solid	  (4.9	  g,	  16.96	  mmol,	  59%);	  mp:	  103.3-­‐104.2	   oC;	  TLC	   (Et2O:light	   petroleum,	  10:90	  v/v):	  Rf	   =	  0.38;	   1H	  NMR	   (400	  MHz,	  CDCl3):	  δ	  7.61	  (s,	  2H),	  5.99	  (s,	  1H),	  1.26	  (s,	  12H);	  13C	  NMR	  (100	  MHz,	  CDCl3):	  δ	  150.0,	  134.5,	  128.3,	  120.9,	  84.3,	  24.8;	   	   IR	  (film):	  3271,	  2980,	  1592,	  1384,	  1349,	  1230,	  1129,	  961,	  892,	  848,	  788,	  676	  cm-­‐1;	  LRMS	  (m/z,	  ES-­‐):	  287	  ([M	  –	  1]-­‐,	  100%);	  HRMS	  (m/z,	  ES-­‐):	  [M	  -­‐	  H]-­‐	  calcd.	  for	  C12H14O335Cl2B,	  287.0418;	  found,	  287.0405.	  	  
Methyl	   4-­‐(3ʹ′ ,5ʹ′-­‐dichloro-­‐4ʹ′-­‐hydroxy-­‐3-­‐biphenyl)-­‐5-­‐phenylisoxazole-­‐3-­‐
carboxylate	  (22);	  standard	  procedure	  A	  solution	  of	  methyl	  5-­‐phenyl-­‐4-­‐(3-­‐trifluoromethylsulfonyloxyphenyl)isoxazole-­‐3-­‐carboxylate	  19	  (1.9	  g,	  4.47	  mmol)	  and	  the	  boronate	  21	  (1.42	  g,	  4.91	  mmol)	  in	  DMF	  (50	  mL)	  was	  degassed	  by	  bubbling	  nitrogen	  through	  it	  for	  30	  min.	  Aqueous	  sodium	   carbonate	   (2	   M,	   6.7	   mL,	   13.41	   mmol)	   was	   added	   and	   nitrogen	   was	  bubbled	   through	   the	   solution	   for	   a	   further	   15	  min.	   The	   catalyst	   Pd(PPh3)4	   (50	  mg,	  0.045	  mmol)	  was	  added	  and	  the	  mixture	  stirred	  at	  90	  oC	  for	  3	  h	  then	  cooled	  to	   rt	   and	  poured	   into	  EtOAc	   (100	  mL).	  The	  mixture	  was	  washed	  with	  aqueous	  hydrogen	   chloride	   (2	   M,	   100	   mL),	   water	   (100	   mL)	   and	   brine	   (100	   mL),	   then	  
	  dried	   (NaSO4)	   and	   concentrated	   under	   reduced	   pressure.	   Chromatography	  (Et2O:light	  petroleum,	  20:80	  –	  40:60	  v/v)	  of	  the	  residue	  gave	  an	  off	  white	  solid	  that	   was	   recrystallised	   (light	   petroleum:EtOAc,	   70:30	   v/v)	   to	   give	   the	   title	  
compound	  22	   as	  a	  white	   solid	   (900	  mg,	  2.05	  mmol,	  45%);	  mp:	  149.7-­‐150.5	   oC;	  TLC	   (Et2O:light	   petroleum,	  40:60	   v/v):	  Rf	  	  =	   0.26;	   1H	  NMR	   (400	  MHz,	   CDCl3):	   δ	  7.59-­‐7.49	  (m,	  5H),	  7.46	  (s,	  2H),	  7.43-­‐7.34	  (m,	  4H),	  5.91	  (s,	  1H),	  3.92	  (s,	  3H);	  13C	  NMR	  (100	  MHz,	  CDCl3):	  δ	  167.5,	  160.4,	  154.8,	  147.3,	  138.8,	  134.2,	  130.6,	  129.7,	  129.6,	   129.4,	   128.9,	   128.6,	   127.1,	   126.9,	   126.7,	   121.5,	   116.3,	   104.8,	   52.8;	   IR	  (film):	  3404,	  1719,	  1500,	  1465,	  1438,	  1340,	  1296,	  1228,	  1156,	  1030,	  973,	  866,	  820,	  790,	  765,	  688	  cm-­‐1;	  LRMS	  (m/z,	  ES-­‐):	  442	  ([M	  –	  1]-­‐,	  20%),	  440	  ([M	  –	  1]-­‐,	  50),	  438	  ([M	  –	  1]-­‐,	  100);	  HRMS	  (m/z,	  ES-­‐):	  [M	  -­‐	  H]-­‐	  calcd.	  for	  C23H14NO435Cl2,	  438.0305;	  found,	  438.0299.	  	  
Methyl	  4-­‐(3-­‐hydroxyphenyl)-­‐5-­‐methylisoxazole-­‐3-­‐carboxylate	  (25)	  Hydroxylamine	   hydrochloride	   (1.44	   g,	   20.8	   mmol)	   was	   added	   to	   methyl	   2,4-­‐dioxopentanoate	  (2	  g,	  13.89	  mmol)	   in	  MeOH	  (50	  mL)	  and	  the	  reaction	  mixture	  stirred	  under	  reflux	  for	  16	  hours.	  After	  cooling	  to	  rt	  the	  mixture	  was	  poured	  into	  water	  (50	  mL)	  and	  the	  solution	  extracted	  with	  EtOAc	  (2	  ×	  50	  mL).	  The	  extracts	  were	   dried	   (Na2SO4)	   and	   concentrated	   under	   reduced	   pressure	   to	   afford	   the	  methyl	   5-­‐methylisoxazole-­‐3-­‐carboxylate	   (23)	   32	   (1.1	   g)	   used	   without	  purification;	   TLC	   (EtOAc:light	   petroleum,	   20:80	   v/v):	   Rf	   =	   0.50;	   1H	   NMR	   (400	  MHz,	  CDCl3):	  δ	  6.41	  (s,	  1H)	  3.96	  (s,	  3H)	  2.50	  (s,	  3H);	  LRMS	  (m/z,	  ES+):	  142	  ([M	  +	  1]	  +,	  100%).	  
	   N-­‐Bromosuccinimide	   (965	   mg,	   8.578	   mmol)	   was	   added	   to	   methyl	   5-­‐methyl-­‐isoxazole-­‐3-­‐carboxylate	   (23)	   (1.1	  g,	   7.799	  mmol)	   in	   trifluoroacetic	   acid	  
	  (15	  mL)	  at	  0	  oC	  and	  the	  solution	  heated	  under	  reflux	  for	  16	  hours,	  then	  allowed	  to	   cool	   to	   rt	   and	   poured	   onto	   ice-­‐water	   (20	  mL).	   The	   mixture	   extracted	   with	  EtOAc	   (2	   ×	   50	   mL),	   and	   the	   organic	   extracts	   were	   dried	   (Na2SO4)	   then	  concentrated	   under	   reduced	   pressure	   to	   afford	   methyl	   4-­‐bromo-­‐5-­‐methylisoxazole-­‐3-­‐carboxylate	   (24)	   33	   (1.2	   g)	   as	   a	   white	   solid	   used	   without	  purification;	   TLC	   (EtOAc:light	   petroleum,	   20:80	   v/v):	   Rf	   =	   0.40;	   1H	   NMR	   (400	  MHz,	  CDCl3):	  δ	  3.89	  (s,	  3H)	  2.50	  (s,	  3H);	  LRMS	  (m/z,	  ES+):	  221	  ([M	  +	  1]	  +,	  100%).	  	  
	   Aqueous	  sodium	  hydrogen	  carbonate	  (575	  mg,	  6.89	  mmol	  in	  1	  mL	  water)	  was	   added	   to	   methyl	   4-­‐bromo-­‐5-­‐methylisoxazole-­‐3-­‐carboxylate	   (24)	   (500	  mg,	  2.28	  mmol)	   and	  3-­‐hydroxyphenylboronic	   acid	   (346	  mg,	  2.51	  mmol)	   in	  DMF	   (5	  mL)	  at	  0	  oC	  and	  the	  reaction	  mixture	  was	  degassed	  for	  30	  min	  with	  argon.	  The	  catalyst	  Pd(PPh3)2Cl2	  (160	  mg)	  was	  added	  rt	  and	  the	  mixture	  heated	  at	  90	  oC	  for	  5	   h	   then	   cooled	   to	   rt	   and	   poured	   onto	   ice-­‐water	   (20	   mL).	   The	   mixture	   was	  extracted	  with	  EtOAc	  (2	  ×	  50	  mL)	  and	  the	  organic	  extracts	  were	  dried	  (Na2SO4)	  and	   concentrated	   under	   reduced	   pressure.	   Chromatography	   of	   the	   residue	  (EtOAc:light	   petroleum,	   20:80	   v/v)	   gave	   the	   title	  compound	  25	   as	   an	   off-­‐white	  solid	   (150	  mg,	  28%);	  TLC	  (EtOAc:light	  petroleum,	  30:70	  v/v):	  Rf	  =	  0.3;	   1H	  NMR	  (400	  MHz,	   CDCl3):	   δ	   7.30	   (m,	   1H)	   6.90-­‐6.75	   (m,	   3H)	   4.83	   (s,	   1H),	   3.90	   (s,	   3H),	  2.45	  (s,	  3H).	  
	  
Recombinant	  protein	  production	  The	   Rv2234	   and	   Rv0153c	   genes,	   encoding	  MptpA	   and	  MptpB,	   were	   amplified	  from	   M.	   tuberculosis	   H37Rv	   and	   cloned	   into	   vector	   pET28a	   as	   previously	  described	   11.	   Site-­‐directed	   mutagenesis	   was	   performed	   on	   wild-­‐type	   pET28-­‐MptpB,	  using	  QuikChange®	  (Stratagene),	  to	  generate	  the	  mutants	  H94A,	  Y125A,	  
	  E129A	   and	   R136A.	   His-­‐tagged	   MptpA,	   MptpB	   and	   derivatives	   thereof	   were	  expressed	   in	  Escherichia	  coli	  BL21(DE3),	  with	  expression	   induced	  at	  18°C	  with	  0.5	  mM	  IPTG	  for	  16	  hours,	  and	  purified	  by	  sequential	  nickel-­‐affinity	  (in	  50	  mM	  HEPES,	  500	  mM	  NaCl,	  pH	  7	  buffer)	  and	  anion-­‐exchange	  chromatography	  using	  MonoQ	   column	   (GE	   Healthcare)	   in	   20	   mM	   Tris,	   pH	   8	   and	   eluted	   in	   a	   NaCl	  gradient.	   Fractions	   were	   concentrated	   and	   further	   purified	   on	   a	   Seperdex75	  column	  (Amersham	  Bioscience)	  with	  20	  mM	  Tris,	  300	  mM	  NaCl	  pH	  8.	  The	  VHR	  construct,	   in	   pGEX-­‐4T,	   was	   a	   gift	   from	   Prof.	   Rafael	   Pulido	   (BioCruces	   Health	  Research	   Institute,	   Barakaldo,	   Spain)	   and	   the	   hPTP1B	   in	   pGEX-­‐KG	   a	   gift	   from	  Prof.	  Jeroen	  der	  Hertog	  (Hubrecht	  Institute,	  Utrecht,	  Netherlands).	  The	  plasmids	  were	   transformed	   into	  E.	  coli	   and	  protein	   expression	   induced	   at	  18°C	  with	  0.5	  mM	   IPTG	   for	   16	   hours.	   Purification	   of	   glutathione	   S-­‐transferase	   (GST)-­‐tagged	  proteins	  was	   achieved	   by	   GST	   affinity	   chromatography	   in	   50	  mM	  HEPES,	   500	  mM	  NaCl,	  pH	  7	  buffer	  and	  eluted	  with	  20	  mM	  glutathione.	  GST	  tag	  was	  removed	  by	  protease	  cleavage	  and	  subsequently	  purified	  using	  a	  Superdex	  75	  column	  in	  50	  mM	  HEPES	  buffer	  at	  pH	  7.	  
	  
Inhibition	  assays	  Inhibition	  assays	  were	  performed	  as	  previously	  described13,	  where	  each	  titration	  experiment	  was	  performed	  in	  triplicate,	  and	  in	  at	  least	  three	  independent	  assays.	  Experiments	   were	   conducted	   in	   96-­‐well	   microtiter	   plates	   and	   each	   well	  contained	  a	  100	  μL	  reaction	  mixture	  including	  0.5	  μg	  of	  protein,	  in	  50	  mM	  Tris,	  50	   mM	   BisTris,	   100	   mM	   sodium	   acetate	   buffer	   (pH	   7	   for	   MptpB,	   pH	   6.5	   for	  MptpA,	   pH	   6	   for	   hPTP1B	   and	   pH	   5	   for	   VHR),	   and	   the	   different	   compounds	  dissolved	  in	  DMSO	  at	  a	  concentration	  range	  between	  0-­‐250	  μM.	  Reactions	  were	  
	  incubated	  for	  15	  min	  at	  room	  temperature	  before	  the	  addition	  of	  p-­‐nitro	  phenyl	  phosphate	  (pNPP)	  to	  a	  final	  concentration	  of	  0.35	  mM.	  After	  15	  min	  incubation,	  the	  reactions	  were	  quenched	  by	  the	  addition	  of	  0.5	  M	  NaOH	  and	  the	  absorbance	  at	   405	   nm	  was	   measured.	   Production	   of	   p-­‐nitro	   phenol	   (pNP)	   was	   quantified	  using	  a	  pNP	   (Sigma)	   calibration	   curve	   (2–2000	  µM).	  Control	   reactions	  without	  enzyme	   were	   performed	   to	   account	   for	   the	   spontaneous	   hydrolysis	   of	   pNPP.	  Phosphate	   release	   was	   calculated	   as	   a	   percentage	   of	   the	   specific	   activity	   and	  plotted	  as	  a	  function	  of	  inhibitor	  concentration	  to	  determine	  the	  IC50.	  	  
	  
Computational	  virtual	  screening	  and	  molecular	  docking	  	  The	   computational	   fragment	   screening	  was	  done	  using	   the	  massive	  processing	  algorithm	  (MPA),	  a	  high	  throughput	  virtual	  screening	  genetic	  based	  algorithm	  18,	  
19	  that	  combines	  ligand	  docking	  to	  the	  target	  using	  Autodock4	  34,	  with	  text	  based	  (LINGO)	  similarity	  searches	  of	  the	  compound	  library	  35.	  The	  MPA	  algorithm	  was	  used	  to	  search	  nine	  different	  commercial	  libraries	  that	  contained	  either	  building	  blocks	  (for	  rapid	  synthesis	  approaches)	  or	  fragments	  from	  different	  sources.	  The	  crystal	  structure	  of	  MptpB	  (PDB	  ID:	  2OZ5)	  was	  used	  in	  the	  screening	  and	  a	  grid	  box	   was	   defined	   around	   the	   secondary	   P2	   pocket.	   Compounds	   were	   scored	  according	   to	   their	   calculated	   binding	   energy	   (ΔG)	   and	   their	   mode	   of	   binding	  analysed	   graphically	   using	   PyMol	   (Schrödinger).	   Synthesized	   compounds	  were	  docked	  to	  the	  crystal	  structure	  of	  MptpB	  (PDB	  ID:	  2OZ5),	  using	  AutoDock4	  34.	  All	  compounds	   were	   docked	   using	   the	   default	   parameters	   and	   a	   maximum	   of	   10	  conformations	   were	   generated	   per	   ligand.	   Each	   docking	   conformation	   was	  scored	  according	  to	  their	  calculated	  free	  energy	  of	  binding,	  ΔG.	  	  	  
	  Bacterial	  strains,	  cell	  culture	  and	  infections	  	  
Mycobacterium	   tuberculosis	   strain	   H37Rv	   (ATCC35837,	   drug	   susceptible),	   the	  clinical	   isolate	   “W_565”36	   of	   multidrug-­‐resistant	   M.	   tuberculosis,	   and	  
Mycobacterium	  bovis	  Bacille	  Calmette-­‐Guerin	  (BCG,	  Pasteur)	  were	  grown	  at	  37°C	  in	   Middlebrook	   7H9	   broth	   containing	   0.05%	   Tween	   80	   with	   shaking	   or	   on	  Middlebrook	   7H10	   agar	   (both	   types	   of	  medium	  were	   supplemented	  with	   10%	  oleic	  acid/albumin/dextrose/catalase	  enrichment	  and	  0.5%	  glycerol).	  	  For	   infections	   using	   BCG,	   J774A.1	   macrophages	   (ATCC)	   were	   cultured	   in	  Dulbecco’s	  modified	  Eagle’s	  medium	  (Sigma)	  containing	  glucose	  (25	  mM)	  and	  L-­‐glutamine	  (4	  mM)	  supplemented	  with	  10%	  heat	   inactivated	  fetal	  bovine	  serum	  (FBS,	   Invitrogen)	   at	   37°C	   in	   a	   humidified	   atmosphere	   with	   5%	   CO2.	   For	  infections,	   J774A.1	   cells	   were	   seeded	   in	   96-­‐well	   culture	   plates	   (Corning)	   at	   a	  density	   of	   2	   x103	   per	  well	   (in	   200	  µl	   of	  media)	   and	   incubated	   overnight.	   Cells	  were	   subsequently	   washed	   twice	   in	   pre-­‐warmed	   Dulbecco’s	   PBS	   (Sigma)	   and	  100	   µl	   of	   fresh	   culture	   medium,	   supplemented	   with	   inhibitors	   (dissolved	   in	  dimethyl	  sulphoxide,	  DMSO)	  or	  DMSO	  alone,	  added	  before	  infecting	  with	  BCG	  in	  100	   µl	   of	   medium	   at	   a	   multiplicity	   of	   infection	   (MOI)	   of	   10:1	  (bacteria:macrophage).	  After	  4	  h	  of	  infection,	  cells	  were	  washed	  four	  times	  with	  Dulbecco’s	   PBS	   to	   remove	   extracellular	   bacteria	   and	   200	   µl	   of	   fresh	   culture	  medium	   (supplemented	   with	   inhibitors	   or	   DMSO)	   added;	   this	   was	   defined	   as	  time	  0	  hours.	  At	  24	  hours	  post	  infection,	  the	  cells	  were	  again	  washed	  twice	  with	  Dulbecco’s	   PBS	   and	   fresh	   medium	   (supplemented	   with	   inhibitors	   or	   DMSO)	  added.	   At	   72	   hours	   post	   infection,	   infected	   cells	   were	   lysed	   in	   0.05%	   (v/v)	  Tween	  80	  and	  the	  number	  of	  viable	  bacteria	  in	  each	  well	  determined	  by	  plating	  10-­‐fold	   serial	   dilutions	   on	   Middlebrook	   7H10	   agar	   plates	   in	   triplicates.	   The	  
	  plates	   were	   incubated	   for	   3	   weeks	   at	   37	   °C	   prior	   to	   counting	   the	   number	   of	  viable	  bacteria.	  All	  assays	  were	  performed	  in	  triplicate	  in	  at	  least	  three	  separate	  experiments.	  For	  infections	  using	  M.	  tuberculosis,	  bacteria	  were	  grown	  for	  1	  week	  at	  37ºC	  with	  shaking	  and	  then	  washed	  with	  PBS	  and	  frozen	  (in	  7H9	  with	  15%	  of	  Glycerol)	  at	  a	  concentration	   of	   4x107	   CFU	  ml-­‐1.	   THP1	  macrophage	   cells	  were	   sub-­‐cultured	   in	  RPMI	   1640	   (Gibco),	   supplemented	   with	   10%	   FBS	   and	   4	   mM	   L-­‐glutamine	   and	  then	  1x106	   cells	  were	  aliquoted	  per	  well	   (6-­‐well	  plates)	  and	   treated	  with	  PMA	  overnight.	  The	  media	  was	  removed	  the	  following	  day	  and	  the	  cells	  were	  washed	  with	  PBS,	  and	  1.5	  ml	  of	  fresh	  RPMI	  (with	  10%	  FBS)	  and	  inhibitors	  (0,	  20	  or	  80	  
µM	  in	  DMSO)	  was	  added,	  before	  infecting	  with	  thawed	  M.tuberculosis	  at	  MOI	  of	  1:1.	  After	  3	  hours	   of	   infection,	  THP1	   cells	  were	  washed	  4	   times	  with	  PBS,	   and	  fresh	  RPMI	  was	   added.	  After	   24	  hours	   the	  media	  was	   removed	   and	   cells	  were	  washed	  with	  PBS	  prior	  to	  the	  addition	  of	  fresh	  RPMI	  and	  inhibitor	  (20	  or	  80	  µM,	  dissolved	   in	   DMSO).	   At	   72	   hours	   post	   infection,	   cells	   were	   washed	   with	   PBS,	  lysed	   with	   0.05%	   SDS	   and	   plated	   onto	   7H10	   media	   to	   determine	   bacterial	  numbers.	  Plates	  were	  counted	  after	  3	  weeks	  of	  growth	  at	  37	  °C	  (all	  experimental	  points	   were	   plated	   as	   10-­‐fold	   serial	   dilutions	   in	   duplicates).	   Each	   experiment	  was	  done	  in	  triplicate,	  including	  controls.	  	  
	  
Cytotoxicity	  assays	  Macrophage	  viability	  was	  measured	  using	  the	  (3-­‐(4,5-­‐Dimethylthiazol-­‐2-­‐yl)-­‐2,5-­‐Diphenyltetrazolium	  Bromide)	  (MTT)	  assay	  37.	  Briefly,	  J774A.1	  cells	  were	  seeded	  in	   96-­‐well	   culture	   plates	   (Corning)	   at	   a	   density	   of	   6	   x	   103	   (200µl/well)	   and	  allowed	   to	   adhere	   overnight.	   Fresh	   media	   supplemented	   with	   inhibitors	  
	  (dissolved	   in	   dimethyl	   sulphoxide,	   DMSO)	   or	   DMSO	   only	   were	   subsequently	  added	   to	   each	  well.	   Cell	   viability	   at	   24	   hours	  was	   assessed	   by	   adding	   50	   µl	   of	  filter	   sterilised	   MTT	   (5	   mg	   ml-­‐1	   in	   PBS)	   to	   each	   well	   followed	   by	   a	   4	   hour	  incubation.	   Media	   was	   removed	   and	   200	   µl	   of	   DMSO	   and	   25	   µl	   of	   Sorensen’s	  glycine	  buffer	  were	  added.	  The	  absorbance	  at	  570	  nm	  was	  measured	  in	  a	  plate	  reader.	  	  
	  
Live	  cell	  imaging	  of	  M.	  tuberculosis-­‐infected	  macrophages	  RAW264.7	  macrophages	  were	  grown	  in	  complete	  DMEM	  +	  10	  %	  FBS.	  On	  the	  day	  before	   infection	  with	  RFP,	  M.	   tuberculosis	   (4x	   105	  cells)	  were	   plated	   on	  WillCo	  glass	   bottom	   dishes	   (22mm,	   GWST-­‐3522).	   Cells	   were	   left	   for	   approximately	   6	  hours	  at	  37	  °C	  to	  attach	  before	  transfection	  using	  JetPEI-­‐macrophage	  (polyplus)	  transfection	  reagents.	  EGFP-­‐2xFYVE	  plasmid,	  1.5	  µg,	  and	  4µl	  JetPEI	  transfection	  reagent	  in	  100	  µl	  of	  150	  mM	  NaCl	  were	  used	  for	  transfection	  of	  one	  dish.	  	  	  The	   day	   after	   transfection	   a	   single	   cell	   suspension	   of	   RFP-­‐Mtb	   H37Rv	   was	  prepared	  and	  added	  to	  the	  dish	  at	  MOI	  5:1	  together	  with	  the	  lead	  compound	  13	  (80	  µM).	  Directly	  after	  addition	  of	  bacteria	  the	  cells	  were	   imaged.	   Images	  were	  taken	  every	  30	  seconds	  at	  512x512	  resolution,	  z=3,	  3x	  line	  average	  24.	  
	  
Pharmacokinetic	  evaluations	  Guinea	  pig	  males	  (Durkin	  Hartley)	  were	  used	  to	  evaluate	  the	  pharmacokinetics	  and	   tissue	   distribution	   of	   compounds.	   The	   route	   of	   administration	   was	   either	  intraperitoneal	  (IP)	  or	  oral	  (PO)	  with	  dosage	  varying	  from	  3.5-­‐8	  mgkg-­‐1	  (OP)	  and	  2.5-­‐4	  mg	  kg-­‐1	   	  (IP).	  In	  each	  case	  4	  samples	  were	  collected	  per	  time-­‐point	  at	  0.1,	  0.5,	   2,	   4	   and	  8	  h	  post	  dose	   for	   IP	   and	  0.25,	   0.5,	   2,	   4	   and	  8	  h	  post	  dose	   for	  PO.	  
	  Compounds	   were	   prepared	   in	   10%	   DMSO,	   5%	   Cremaphor,	   85%	   physiological	  saline	   for	   IP	   administration,	   or	   0.5%	   (v/v)	   Tween	   80,	   99.5%	   (v/v)	   0.5%	  Methylcellulose	   for	   oral	   administration.	   Tissue	   samples	   (n=4)	   from	   lung,	   liver	  and	   kidney	   were	   collected	   at	   the	   end	   of	   the	   study	   and	   snap	   frozen	   prior	   to	  bioanalysis.	  	  
Efficacy	  studies	  in	  guinea	  pigs	  	  
All animals were housed in the Public Health Research Institute’s Animal 
Biosafety Level-2 (tolerability) or Animal Biosafety Level-3 (efficacy) 
Research Animal Facility (ICPH RAF), a center of the New Jersey Medical 
School, Rutgers University (NJMS-Rutgers). The animal facility follows the 
Public Health Service and National Institute of Health Policy of Humane 
Care and Use of Laboratory Animals. All experimental protocols were 
approved by the Rutgers Institutional Animal Care and Use Committee 
(IACUC). Female outbred Hartley Duncan Guinea Pigs (~400 g) were used 
in all studies. Tolerability	   studies	   were	   done	   prior	   to	   the	   infection	   models.	  Guinea	  pigs	  (n=5)	  were	  orally	  dosed	  once	  daily	  for	  7	  days	  with	  13	  50,	  or	  100	  mg	  kg-­‐1.	  No	   adverse	  drug	   effects	  were	  observed	   and	  weight	   increases	   of	   >5%	  was	  observed	  in	  all	  animals	  during	  the	  tolerability	  trial.	  Plasma	  and	  lung	  drug	  levels	  were	   analyzed	   at	   2	   and	   24	   hours	   (peak	   and	   trough	   levels)	   after	   the	   last	   dose	  administered.	  	  Drug	  levels	  for	  the	  100	  mg	  kg-­‐1	  orally	  administered	  13	  were	  1748	  ng	  ml-­‐1	  in	  plasma	  and	  623	  ng	  ml-­‐1	  in	  lungs	  at	  2	  hours,	  and	  35	  ng	  ml-­‐1	  in	  plasma	  at	  24	  hours.	  	  An	  acute	  model	  of	  TB	  infection	  was	  used	  to	  assess	  the	  efficacy	  of	  compound	  13	  
	  as	  monotherapy	  in	  reducing	  bacterial	  burden	  during	  early	  acute	  phase	  of	  growth	  in	   the	   lungs.	   In	   this	   infection	   model,	   guinea-­‐pigs	   were	   infected	   with	   96	   CFU	  (Average,	  ±	  27	  SEM)	  of	  M.	  tuberculosis	  H37Rv	  via	  aerosol	  inhalation.	  The	  animals	  were	  randomized	   into	  groups	  of	  4	  Guinea	  pigs	  per	   treatment	  or	  vehicle	  group.	  The	   infection	   was	   confirmed	   by	   lung	   bacterial	   burden	   enumeration	   from	   3	  animals	  sacrificed	  at	  24	  hours	  post	  exposure.	   	  Compound	  13	  (100	  mg	  kg-­‐1)	  and	  the	  vehicle	  were	  orally	  administered	   (feeding)	  daily	   for	  4	  weeks	   starting	  at	  24	  hours	   post	   infection.	   After	   4	   weeks	   of	   treatment,	   all	   guinea-­‐pigs	   on	   the	   study	  gained	  weight	  and	  had	  normal	  behavior	  and	  fecal	  output.	  A	  chronic	  model	  of	  TB	  infection	  was	  used	  to	  assess	  the	  efficacy	  of	  compound	  13	  as	   monotherapy	   (100	   mg	   kg-­‐1).	   No	   morbidity	   was	   observed	   throughout	   the	  study.	   Guinea-­‐pigs	   were	   infected	   with	   low	   dose	  M.	   tuberculosis	   with	   63	   CFU	  (Average,	   ±	  18	  SEM)	  by	   aerosol	   inhalation.	  The	   animals	  were	   randomized	   into	  groups	   of	   5	   guinea	   pigs	   per	   treatment	   or	   vehicle	   group.	   The	   infection	   was	  confirmed	  by	  lung	  bacterial	  burden	  enumeration	  from	  3	  animals	  sacrificed	  at	  24	  hours	  post	  exposure.	  The	  remaining	  animals	  were	  left	  untreated	  for	  4	  weeks	  to	  develop	  a	  steady	  state	  of	  TB	  burdens	   in	   the	   lungs.	  After	  28	  days	  of	   infection,	  4	  animals	   were	   sacrificed	   and	   bacterial	   burdens	   of	   the	   lungs	   and	   spleens	   were	  enumerated	  to	  establish	  a	  baseline	  burden	  level	  prior	  to	  the	  start	  of	  treatment.	  Compound	  13	  (100	  mg	  kg	  -­‐1)	  and	  the	  vehicle	  were	  orally	  administered	  daily	  for	  4	  weeks	  starting	  at	  28	  days	  post	   infection.	  After	  4	  weeks	  of	   treatment,	  all	  guinea	  pigs	   on	   the	   study	   did	   have	   varying	   increases	   in	   weight,	   and	   exhibited	   normal	  behavior	   and	   fecal	   output.	   	   For	   statistical	   analysis,	   the	   CFUs	   are	   converted	   to	  logarithms,	   and	   evaluated	   by	   a	   one-­‐way	   ANOVA	   followed	   by	   a	   multiple	  comparison	   analysis	   of	   variance	   by	   Tukey	   and/or	   Dunnett's	   test	   (Graphpad	  
	  Prism	  6.0	  software	  program).	  Differences	  were	  considered	  significant	  at	  the	  95%	  level	   of	   confidence.	   For	  both	   the	   acute	   and	   chronic	   infection	   studies,	   the	   lungs	  and	   spleens	   were	   graded	   from	   1-­‐4	   based	   on	   a	   modified	   Mitchison	   virulence	  scoring	   from	   Jain	   et	   al.27.	   The	   scoring	   was	   based	   on	   gross	   pathological	  examination	   of	   inflammation,	   extent	   of	   involvement	   and	  necrosis,	   number	   and	  relative	  size	  of	  lesions.	  	  
	  
Histopathology	  For	   histology,	   portions	   of	   guinea-­‐pig	   lungs	   and	   spleens	   were	   fixed	   in	   neutral	  buffered	   formalin	   then	   embedded	   in	   paraffin.	   Sections,	   (~5	  μm),	  were	   cut	   and	  stained	  with	  hematoxylin	  and	  eosin.	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